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ABSTRACT: β-alanine (BA) supplementation is one of the world’s most commonly used 43 
sports supplements, and its use as a nutritional strategy in other populations is ever-increasing, 44 
due to evidence of pleiotropic ergogenic and therapeutic benefits. Despite its wide-spread use, 45 
limited understanding of potential adverse effects is available. In order to address this, a 46 
systematic risk assessment and meta-analysis, based on PRISMA guidelines, was undertaken. 47 
Four databases were searched using keywords and MESH headings. All human and animal 48 
studies that investigated an isolated, oral, BA supplementation strategy were included. Data 49 
were extracted according to 5 main outcomes, including: 1) Side-effects reported during 50 
longitudinal trials, 2) Side-effects reported during acute trials, 3) Effect of supplementation on 51 
health-related biomarkers, 4) Effect of supplementation on related elements (taurine and 52 
histidine), 5) Outcomes from animal trials. Quality of evidence for outcomes were ascertained 53 
using GRADE recommendations and all quantitative data were meta-analysed using multi-54 
level models grounded in Bayesian principles. 101 human and 50 animal studies were included. 55 
Paraesthesia was the only reported side-effect and had an estimated odds ratio of 8.9 (95%CrI: 56 
2.2, 32.6) with supplementation relative to placebo. Participants in active treatment groups 57 
experienced similar drop-out rates to those receiving the placebo treatment [Odds ratio: 0.72 58 
(95%Crl: 0.50, 1.05)]. BA supplementation caused a small increase in ALT content (ES: 0.274, 59 
Crl: 0.04, 0.527) although mean data remained well within clinical reference ranges. Meta-60 
analysis of human data showed no main effect of BA supplementation on taurine (ES; 0.002; 61 
95%Crl: -0.48, 0.47) or histidine (-0.15; 95%Crl: -0.64, 0.33). A main effect of BA 62 
supplementation on taurine content was reported for murine models, but only when the daily 63 
dose was ≥3% BA in drinking water. Intervention duration did not moderate this effect. The 64 
results of this review indicate that BA supplementation within the doses used in research 65 
designs, does not adversely affect those consuming it.  66 
KEYWORDS: Carnosine; taurine; histidine; paraesthesia; safety; adverse effects.  67 
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INTRODUCTION 68 
The primary role of carnosine (β-alanine-L-histidine) in skeletal muscle metabolism is to act 69 
as an intracellular buffer (1), with additional potential actions including the reduction of 70 
reactive oxygen/nitrogen species, and/or calcium regulation (2,3). β-alanine (BA) availability 71 
is the limiting step in intra-muscular carnosine (MCarn) synthesis. Accordingly, 72 
supplementation increases MCarn content (4,5), the ergogenic potential of which is well 73 
established. A recent meta-analysis confirmed the efficacy of BA supplementation to improve 74 
high-intensity exercise performance, with optimum benefit reported for capacity based 75 
assessments lasting between 30 seconds and 10 minutes (6). Accordingly, BA is one of just 76 
five sports supplements recognised by the International Olympic Committee as having 77 
sufficient evidence of efficacy to warrant its use in specific situations (7). Additionally, 78 
therapeutic supplementation with BA is gaining in popularity. Recently, the therapeutic 79 
potential of carnosine was reviewed (8) and a wide range of targets and conditions that may be 80 
improved by BA or carnosine supplementation were highlighted. These included protection 81 
against the effects of senescence (9), conveying a neuro-protective influence (10,11), inhibition 82 
of tumour growth (12), improved clinical outcomes in participants suffering from Parkinson’s 83 
disease (13), enhanced glucose sensitivity (14) and accelerated recovery following acute 84 
kidney failure (15). Much of this evidence was based on animal or in-vitro models, and the 85 
efficacy of BA supplementation to meaningfully impact these parameters in clinical trials has 86 
yet to be ascertained. The therapeutic potential of BA supplementation represents a topical and 87 
exciting progression of the current evidence base, and research in this area is likely to 88 
exponentially increase in the coming years, as ever-more targets are identified for this 89 
pleiotropic nutritional agent.  90 
In contrast to a large and increasing evidence base for ergogenic and therapeutic effects of BA 91 
supplementation, limited information is available on the safety of this nutritional strategy. 92 
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Regular risk assessment of common nutritional supplements and ergogenic aids is essential as 93 
nutrients generally exert a biphasic dose response, whereby optimal intakes exert a stimulatory 94 
and beneficial response, while lower or higher intakes may be harmful or inhibitory. 95 
Theoretical concerns related to an excess intake of beta-alanine include a possible reduction of 96 
taurine and/or free histidine content. Reduced intra-cellular taurine may occur as elevated BA 97 
availability increases competition for their shared transporter, Tau-T (16). Histidine is also 98 
required for carnosine synthesis, and if not matched by dietary intake, the free histidine pool 99 
may become depleted as a result of chronic BA supplementation (17). Additionally,  BA 100 
supplementation has been reported to cause acute paraesthesia, which has been described as an 101 
uncomfortable sensation on the surface of the skin that occurs within 10 – 20 minutes following 102 
ingestion (4). Little is known about the occurrence or physiological consequences of these 103 
outcomes. The aim of the current investigation, therefore, was to undertake a systematic risk 104 
assessment of BA supplementation, comprising comprehensive review and analysis 105 
procedures, to synthesise and evaluate all available evidence from both human and animal 106 
trials.  107 
METHODS 108 
This risk assessment followed recommendations from the Council for Responsible Nutrition 109 
(CRN) Vitamin and Mineral Safety, 3rd Edition (18), which are commonly used to risk assess 110 
nutritional supplements (19,20). The protocol was designed in accordance with PRISMA 111 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (21). The 112 
review was prospectively registered in an international register of systematic reviews 113 
(PROSPERO registration no. CRD42017071843).  114 
 115 
 116 
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Study Selection:  117 
Study selection was guided by the PICOS (population, intervention, comparator, outcomes and 118 
study design) approach, and the criteria within each of these categories were as follows:  119 
• Population: Human populations were restricted to healthy individuals of any age or 120 
activity level. Animal models were considered for inclusion only if conducted on 121 
healthy, wild-type mammals.  122 
• Intervention: Original studies investigating the effects of isolated oral BA 123 
supplementation interventions were considered for inclusion in the review.  124 
• Comparator: No human comparators were required, but randomised, blinded, placebo-125 
controlled studies were assigned a higher quality rating and prioritised in the 126 
interpretation of results.  127 
• Outcomes: Human data were analysed according to 4 outcomes, namely 1) side-effects 128 
reported during longitudinal trials, 2) side-effects reported during acute trials, 3) effect 129 
of supplementation on health-related biomarkers and 4) effect of supplementation on 130 
related compounds. For the animal trials, data related to species, dosing strategy, study 131 
aims and primary outcomes were extracted. Dosing strategy was reported as 132 
intervention length (days), the concentration of BA provided in the drinking water (%) 133 
or chow, and the total dose ingested by each animal (mgBA.gBW-1). Daily intake 134 
(g.day-1) was based on the mean weight of the animals in the BA group, estimated as 135 
the mean of the start and end weights reported. If not reported, weights were estimated 136 
using normative data from the same strain (http://www.arc.wa.gov.au/?page_id=125). 137 
If specific fluid intakes were not reported, these were estimated assuming an intake of 138 
0.1ml.g-1 for rats, and 0.15ml.g-1 for mice ().  139 
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• Study Design: Only studies that used an intervention-based study design were included 140 
within the review. 141 
Search Strategy 142 
A three-stage screening strategy (title/abstract screening; full-text screen; full text appraisal) 143 
was independently undertaken by two reviewers. The search was conducted using 4 databases 144 
(Medline; Embase; Sport Discus and Web of Science) with the terms “beta alanine” OR 145 
“carnosine” concatenated with “intervention” OR “trial” OR “supplementation” OR “health” 146 
OR “safety” OR “paraesthesia” OR “taurine” OR “side-effect” OR “adverse effect” OR 147 
“toxicity”. In addition, MESH heading searches, with the key-term beta-alanine were 148 
conducted using Medline and Embase, and with database specific subheadings. Searches were 149 
limited to original studies in English published between 1980 and 2018. The final searches 150 
were completed in September 2018.  151 
Quality Appraisal and Data Extraction 152 
All data were extracted using a pre-piloted spreadsheet, and independently verified by a second 153 
member of the review team. Quality ratings for outcomes 1 and 2 (side-effects reported in all 154 
acute and longitudinal human trials) were assigned using the recommendations of the GRADE 155 
working group (Grading of Recommendations Assessment Development and Evaluation) (22). 156 
An a-priori ranking of high, moderate or low was assigned, based on whether the study was a 157 
randomised placebo-controlled trial, a non-randomised placebo controlled trial or a non-158 
randomised and non-placebo-controlled intervention trial. Studies were also provided an a-159 
priori ranking of high quality if they used a matched pair allocation design. Studies were then 160 
assessed, and down-graded a level if appropriate, based on the response to 3 questions, i.e. 1) 161 
were participants blinded to the treatment? 2) were side-effects reported in the study? 3) were 162 
participants specifically instructed to report side-effects? This procedure allowed the quality of 163 
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evidence for each outcome to be categorised as “high”, “moderate”, “low” or “very low”, with 164 
the cumulative outcome score based on the median score assigned.  165 
Data Analysis 166 
All meta-analyses were conducted within a Bayesian framework enabling studies with zero 167 
events to be included without requiring correction factors. In addition, Bayesian methods 168 
enabled log odds ratios to be modelled without assuming a normal distribution and provided 169 
an efficient means of down-weighting potentially biased studies, i.e., those without a control 170 
condition (23). Hierarchical Bayesian random effects models were used to meta-analyse 171 
outcome data on cases reporting paraesthesia and drop outs. Binomial specifications were used 172 
at the first level of the model to estimate probability of an event, with parameters allowed to 173 
vary across studies. Intercept terms for logit transformed probabilities were estimated for the 174 
control comparison and an additional effect term included for active supplementation. Effect 175 
terms were assumed to follow a normal distribution at the second level of the hierarchical 176 
model, with the mean representing the average log odds ratio across all studies and the variance 177 
indicating study-to-study variability. Non-informative normal and uniform priors were used 178 
for the mean and variance parameters, respectively.  179 
The effects of BA supplementation on tissue taurine and histidine content in human and animal 180 
populations were quantified using standardized mean difference effect sizes. Standard 181 
formulae for raw score effect sizes and associated sampling variances were used for 182 
independent-groups post-test (animal studies only), single-group pretest-posttest (24) and 183 
pretest-posttest-control study designs (25). Observed effect sizes were assumed to follow a 184 
normal distribution with mean identified by hyper-parameters representing the average effect 185 
across all studies and variance indicating study-to-study variability. To control for potential 186 
bias in human studies featuring non-controlled designs, a sensitivity analysis comprising down-187 
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weighting of effect sizes through a hierarchical power prior model was included (26). Finally, 188 
a meta-regression controlling for daily dose (less than, or equal to, 3%) and total cumulative 189 
dose (mgBA.gBW-1) was included for animal studies measuring taurine levels post-190 
supplementation. Inferences from all Bayesian models were performed on posterior samples 191 
generated by Markov Chain Monte Carlo with 95% credible intervals (CrIs) constructed. 192 
Models were run in OpenBUGS (version 3.2.3, MRC Biostatistics Unit, Cambridge UK) and 193 
in R (version 3.3.1 R Development Core Team) using the R2OpenBugs package 194 
(https://CRAN.R-project.org/package=rbugs). 195 
  196 
RESULTS 197 
Study Characteristics 198 
One hundred and one human intervention studies (94 longitudinal and 8 acute, with one study 199 
comprising both acute and longitudinal arms; (4)), and 50 animal studies were included in the 200 
review (see Figure 1). In total 2,268 humans were included in the final analyses (1,820 men 201 
and 448 women), with 1,295 of these consuming the active BA supplement. The majority of 202 
studies were conducted on healthy young adults, and participants had a median (IQR) age of 203 
23.5 (5.5) yrs. Seven studies were conducted using a population with a mean age > 50 yrs 204 
(9,27–32) and 5 studies were conducted using adolescent populations (mean age: 10 - 19 years 205 
(33–37). The majority of longitudinal studies were conducted using athletic groups (48%), or 206 
recreationally trained (34%) populations, with the remaining described as being untrained 207 
(8%), or undefined (10%). Further information related to the training type and status of 208 
participants is provided in Supplementary Files 1 and 2 (SF 1 & 2). Three inclusions within the 209 
review were based on data sourced outside of the described search-strategy. Two of these were 210 
presented at international conferences (38,39) and the other was a doctoral thesis, (40). The 211 
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decision to include these datasets was based on their relevance to the topic area, along with the 212 
completeness of data and design information available. 213 
Outcome 1: Side-effects reported during longitudinal trials 214 
Ninety-four longitudinal studies, comprising 99 outcomes, were identified, and are described 215 
in Supplementary File 1. The median (IQR: range) intervention period and daily dose was 28 216 
(14: 7-168) days, and 6 (1.65: 1.6-12) g.day-1, resulting in a total cumulative dose of 179.2 217 
(60.5: 34.3-1075.2) g. The quality of evidence for side-effects reported was primarily moderate 218 
or low (23% high; 34% moderate; 33% low; 9% very low; Figure 2 Panel A). Ninety-one 219 
percent of studies were initially allocated an a-priori rating of “high quality”, but most were 220 
subsequently downgraded based on the secondary nature of side-effect reporting, which 221 
resulted in the provision of limited information regarding side-effects experienced and the 222 
mode of assessment. Meta-analysis of withdrawal rates between participants allocated to BA 223 
or placebo groups were non-significant (Odds ratio: 0.72; 95%CrI: 0.50, 1.05). Two additional 224 
sensitivity analyses were conducted after: 1) removing data from studies that reported very 225 
high withdrawal rates from both groups (28,41) (Odds ratio: 0.67; 95%CrI: 0.39 – 1.01) and 2) 226 
including data only from studies that specifically reported withdrawal information (Odds ratio: 227 
0.74; 95%CrI: 0.45 – 1.05). These sensitivity analyses did not alter the original findings. 228 
Analysis of incidence of paraesthesia was conducted with data from studies that were assigned 229 
a “high” quality rating only (n = 22, with 285 and 219 participants assigned to the BA and PLA 230 
groups respectively). Incidence of paraesthesia was 18.6% in the active treatment group and 231 
5.7% in the placebo group. Meta-analysis of reported incidences of paraesthesia demonstrated 232 
a significantly increased likelihood of paraesthesia reporting with active supplementation 233 
(Odds ratio: 8.9; 95%CrI: 2.2 – 32.6). Wide variation in both the incidence and severity of 234 
paraesthesia symptoms were evident. This finding, along with wide heterogeneity in study 235 
design, dosing protocols, compliance monitoring and mode of side-effect reporting precluded 236 
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statistical identification of factors that moderated paraesthesia. One longitudinal study 237 
examined paraesthesia occurrence when participants were provided a fixed dose of 6g.day-1 of 238 
BA for 28 days, in either sustained or rapid release formulations (42). The group who ingested 239 
the rapid release formulation reported a more frequent paraesthesia occurrence than those who 240 
consumed the sustained release formulation. This group reported a similar paraesthesia 241 
occurrence to the placebo group. No differences in compliance were identified between the 242 
groups.  243 
Outcome 2: Side-effects reported during acute trials  244 
Eight studies, comprising nine outcomes, reported data related to side-effects experienced 245 
during acute BA supplementation were identified (4,40,43–49), and are described in 246 
Supplementary File 2. The median (IQR: range) dose ingested was 1.6 (0.38: 0.8-3.2) g and 247 
the quality of evidence for this outcome measure was primarily “high” (56% high, 22% 248 
moderate, 22% low, Figure 2 Panel B). Statistical meta-analyses of outcomes were not 249 
conducted due to the small number of studies available, combined with large heterogeneity in 250 
study design and outcome measures, and so a narrative synthesis is presented. Similar to 251 
longitudinal trials, paraesthesia was the only side-effect reported. The extent and time to peak 252 
blood BA concentration emerged as the primary determinant of the occurrence and intensity 253 
of paraesthesia. This was first investigated by Harris et al. (2006), who administered different 254 
acute BA forms and doses. BA (40mg.kgBM-1) ingested in the form of carnosine and anserine 255 
contained in chicken broth did not result in paraesthesia, while an equivalent intake of BA in 256 
its pure form invoked responses of tingling, itch and irritation, representative of paraesthesia 257 
(4). Response occurred in a dose related manner with 40mg.kgBM-1 (~3.2g) causing sensations 258 
that were considered unpleasant by all participants, and intolerable by 2. In contrast, lower 259 
doses (10 and 20 mg.kgBM-1/~0.8 and 1.6g) invoked similar sensations, but of milder 260 
intensities. Decombaz et al. (2012), investigated response to an equivalent BA intake (1.6g), 261 
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provided in slow-release capsules or in its pure form dissolved in aqueous solution. 262 
Participants completed questionnaires related to paraesthesia symptoms in parallel with blood 263 
sampling. Only BA in solution produced evident sensations, with the intensity described as 264 
"pins and needles". Sensory response anticipated and paralleled that of plasma BA 265 
concentration, and paraesthesia symptoms were influenced by the extent and time to peak 266 
plasma BA concentration (44). Stautemas et al. (2018) investigated the influence of acute 267 
ingestion of a fixed (1.4g) vs a weight relative (10mg.kgBW-1) dose on BA pharmacokinetics. 268 
Paraesthesia was not reported by any participant consuming the weight-relative dose, while 2 269 
of the 28 participants experienced paraesthesia in the fixed dose group, the timing of which 270 
matched their individual Cmax. Some evidence exists suggesting that ethnicity, sex (46) or the 271 
individual’s body size (40) may moderate the occurrence, or intensity, of paraesthesia 272 
experienced. More specifically, Asians, women and lighter individuals (<75) reported stronger 273 
or more frequent experience of paraesthesia compared to Caucasians, men and men heavier 274 
than 85kg.  275 
Outcome 3: Effect of BA supplementation on health-related biomarkers 276 
Seven studies reported data on the influence of BA supplementation on circulating health-277 
related biomarkers (4,9,28,39,50–52), comprising 220 individuals, with 87 of these taking the 278 
active BA supplement. These studies used a median (IQR) total cumulative dose of 179.2 (84)g. 279 
Studies were conducted using older male and female participants (9,28), healthy young males 280 
(4,39,50), healthy young men and women (51) or trained cyclists (52). No individual study 281 
reported a significant change to any of the measured biomarkers. Meta-analyses were 282 
conducted on any marker that was measured in 2 or more studies and results are presented in 283 
Table 1. A statistically significant effect of BA supplementation was obtained for alanine 284 
aminotransferase (ES: 0.274; 95%CrI: 0.04, 0.527), while trends toward significantly increased 285 
alkaline phosphatase (ES: 0.434; 95%CrI: -0.067, 0.811) and sodium (ES: 0.497; 95%CrI: -286 
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0.033, 1.063) were also observed. Additionally, Harris et al. (2006) conducted a 12-lead ECG, 287 
and reported no change to cardiac function following a 4 week BA supplementation 288 
intervention (4).     289 
Outcome 4: Effect of BA supplementation on taurine and histidine (human data) 290 
Five studies reported data on the effect of BA supplementation on taurine (4,17,38,39,53) and 291 
four on histidine (17,42,51,54). Taurine content was measured in 63 individuals with 45 292 
allocated to the active BA supplement, while histidine content was measured in 73 individuals 293 
with 55 allocated to the active BA supplement. Meta-analyses indicated that, in humans, the 294 
BA supplementation protocols employed did not exert an effect on skeletal muscle taurine (ES: 295 
0.002; 95%CrI: -0.48, 0.47, Figure 3) or histidine (ES: -0.15; 95%CrI: -0.64, 0.33). Sensitivity 296 
analyses conducted to control for potential bias in studies not including a placebo comparative 297 
group did not meaningfully change results attained for any of these parameters (data not 298 
shown).  299 
Outcome 5: Outcomes from animal studies 300 
Fifty animal studies were included in the review, and an overview of these studies is provided 301 
in Supplementary File 3. Meta-analyses of all studies including data on tissue taurine content 302 
in both BA supplemented and pair-fed control murines indicated a main effect of BA 303 
supplementation on taurine content (ES: -1.94; 95%CrI: -2.39, -1.52). Substantial variation 304 
existed in relation to the potential effect of moderators including daily dose, intervention 305 
duration, total cumulative dose and tissue type. Following a sequential modelling approach to 306 
account for potential moderators and reduce between-study heterogeneity, a final meta-307 
regression was performed using data from cardiac or skeletal muscle only, and included a 308 
binary variable (daily dose: <3% or ≥3% of BA in drinking water), and a covariate (Total 309 
cumulative dose (TCD) mgBA.gBW-1). No effect of BA supplementation on taurine content 310 
14 
 
 
 
was shown when a daily dose of <3% was ingested (ES: -0.32, 95%CrI: -0.80, 0.14, Figure 4), 311 
while a dose of 3% induced a significant reduction to tissue taurine content (ES: -2.71, 95%CrI: 312 
-3.33, -2.15, Figure 5). The difference between these doses was statistically significant (ES: -313 
2.35; 95%CrI: -3.27, -1.48). No effect of TCD (ES: -0.007; 95%CrI: -0.030, 0.017) was 314 
obtained, nor an interaction between daily dose and TCD (ED: 0.021; 95%CrI: -0.010, 0.051). 315 
Only one study reported data on the effect of BA supplementation on tissue histidine content 316 
(55). This study provided data on histidine content in 5 brain sites, and no effect of BA 317 
supplementation was identified (ES: 0.57; 95%CrI: -0.24, 1.39). 318 
 319 
DISCUSSION 320 
No adverse effects of oral beta-alanine supplementation, within the doses and intervention 321 
durations investigated, were identified within this systematic risk assessment. Meta-analysis of 322 
animal data indicates that BA supplementation of at least 3% is required to reduce cardiac or 323 
skeletal muscle tissue taurine content, and that this reduction is not impacted by intervention 324 
duration.  Meta-analysis of human data showed no effect of BA supplementation on muscle 325 
taurine or histidine content, likely due to the lower relative doses employed in human studies. 326 
Paraesthesia was the only side-effect identified during human trials, however no evidence 327 
exists to indicate that this is harmful, and thus it is not considered to represent an adverse event. 328 
Participants in the active treatment groups were not found to experience higher drop-out rates 329 
than those consuming a placebo. Although a significant effect of BA supplementation on ALT 330 
content was identified, the effect was small, and supplementation did not meaningfully alter 331 
any of the other health-related biomarkers reported.  332 
Effect of BA supplementation on health-related biomarkers 333 
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A wide range of clinical biomarkers were investigated pre and post-supplementation, including 334 
indicators of renal, muscle and hepatic function, along with various clinical haematological 335 
markers. No individual study reported a significant effect of BA supplementation on any of 336 
these biomarkers (4,9,28,39,50,51). Additionally, two studies conducted additional analyses, 337 
to identify the proportion of individuals with values outside of normative ranges for each of 338 
the biomarkers identified, and whether this varied between the BA and PLA group (39,50). No 339 
trends were apparent from either of these studies. Meta-analysis of any biomarker that was 340 
measured in two or more studies, did however, show a main effect of BA supplementation on 341 
ALT content, along with trends toward an increase in sodium and alkaline phosphatase (ALP). 342 
ALT is a transaminase enzyme, which is primarily present in the liver. Liver damage may cause 343 
ALT to “leak” into the bloodstream, and thus elevated blood levels can be indicative of liver 344 
dysfunction. Statistical meta-analysis indicated a “small” effect of BA supplementation on 345 
blood ALT content (ES: 0.274; CrI: 0.04, 0.527). Considering the pooled SD of all baseline 346 
data reported (11.7), this would correspond to a mean increase of ~3.2 U.L-1 for each participant 347 
within the BA groups. Considering that mean baseline ALT content was 22.5 U.L-1, this small 348 
increase would still result in blood ALT levels well within clinical reference ranges, which are 349 
typically considered to be <40-55 U.L-1, although wide variation in individual lab reference 350 
ranges do exist. Interestingly, it has previously been reported that only a small amount of 351 
supplemented beta-alanine (~3%) is actually used for carnosine synthesis (56) with the rest 352 
being used in processes such as transamination, or energy delivery (57). Given that ALT is a 353 
transaminase enzyme, it seems plausible to suggest that the small increases identified may 354 
represent increased transamination activity due to elevated BA availability. Alternatively, it is 355 
widely recognised that ALP and ALT are non-specific biomarkers, impacted by a range of 356 
factors, including physical activity (58). Given that BA supplementation is widely recognised 357 
to increase capacity for performance of high-intensity exercise, another potential explanation 358 
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for this finding may be increased activity within the BA group. These suggestions are of course 359 
speculative, and further research on the broader metabolic consequences of BA 360 
supplementation is required to enhance understanding in this area.  361 
 362 
Effect of BA supplementation on taurine and histidine 363 
The meta-analysis conducted on animal trials provides strong evidence that BA 364 
supplementation can cause a reduction in tissue taurine content at high doses (defined here as 365 
at least 3% solution in drinking water; ES: -2.71, 95%CrI: -3.33, -2.15), but not at lower doses 366 
(defined as <3% in drinking water, -0.32, 95%CrI: -0.80, 0.14). No evidence of an effect of 367 
BA supplementation on taurine content was identified in humans (ES: 0.002; 95%CrI: -0.48; 368 
0.47). This is likely due to the substantially lower dose typically used in the human studies, 369 
when compared to the animal studies. The highest dose used in human studies was 6.4g.day-1 370 
(39). For an 80kg male, this is the equivalent of 80mg.kg.day-1.  Assuming that a typical adult 371 
male mouse or rat weighs 25 or 400g respectively, and drinks 0.15 or 0.1 ml.g.day-1, this would 372 
equate to an intake of 4500 or 3000 mg.kg.day-1 for a mouse or rat who is provided 3%BA in 373 
drinking water, which is ~34 – 53 fold greater than the typical human dose provided. Direct 374 
murine-to-human inferences are limited due to vastly different metabolic rates along with 375 
species-specific biochemistry, however, the available evidence does appear to indicate that the 376 
daily dose typically used in human studies (~ 3.2 - 6.4 g.day-1) is not of the magnitude required 377 
to measurably reduce muscle taurine content. 378 
No effect of total cumulative dose (TCD), nor of an interaction between TCD and daily dose, 379 
was obtained, indicating that intervention duration does not moderate the influence of BA on 380 
taurine, and that this effect does not increase over time. Lake et al (1988) reported that cardiac 381 
taurine content in rats was significantly reduced after 1, 2 and 3 weeks of treatment with 3% 382 
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BA in drinking water, although the magnitude of effect was smaller after 3 weeks compared to 383 
that identified at weeks 1 and 2, while after 6 weeks of treatment the BA group were not 384 
different to the pair-fed control animals (59). These data suggest that not only does the 385 
influence of BA not increase with time, it may in fact be reversed. Recently, a down-regulation 386 
of the BA/taurine transporter Tau-T was reported in humans ingesting 6.4g.day-1 of BA for 24 387 
weeks (5), which may potentially represent a means of maintaining taurine homeostasis during 388 
periods of elevated BA availability. Further research is required to elucidate the mechanistic 389 
pathways through which both carnosine and taurine are regulated during BA supplementation.  390 
Recently, it has been reported that BA supplementation may reduce plasma and muscle free 391 
histidine availability (17) and this was suggested as having potentially adverse consequences 392 
for muscle protein synthesis. The current meta-analysis showed no main effect of BA 393 
supplementation on histidine, in either human or murine models. It is important to highlight, 394 
however, that limited animal data was available, and the only animal study available 395 
investigated the influence of 100mg.kg-1 BA on brain histidine content (55). An influence of 396 
higher BA doses, as was observed in the taurine meta-analysis, or an influence on other tissues, 397 
cannot therefore, be ruled out.  398 
The animal data described in Supplementary File 3 provided insight into the potential 399 
alterations to skeletal, cardiac, hepatic, renal and nervous function that may occur in response 400 
to very high BA doses used within these studies. Interestingly, the altered physiological 401 
processes described therein were neither exclusively positive nor negative in nature. For 402 
example, BA supplementation has been reported to exert both a protective (60) and a harmful 403 
(61) influence on cardiac function in rats, with limited consensus on the factors that dictate the 404 
nature of this response. An important limitation of many of the available animal studies, was 405 
that they typically focused on the influence of BA induced taurine deficiency, and rarely 406 
considered the broader actions of BA supplementation, which include increased carnosine, or 407 
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the independent action of BA per se.  For example, Horvath et al. (2016) investigated the 408 
influence of taurine supplementation, and BA induced taurine depletion, on skeletal muscle 409 
contractility and fatigue resistance in wild-type and mdx mice (62), and reported that both 410 
interventions had a positive effect on muscle function. BA supplementation induced increases 411 
to muscle carnosine content are known to enhance skeletal muscle function and high-intensity 412 
exercise performance (2), and these results were likely due to increased carnosine, rather than 413 
to the taurine depletion that was reported. Conversely, Lu et al. (1996) reported a neuro-toxic 414 
influence of BA supplementation in cats, a species that are known to have a low capacity for 415 
endogenous taurine synthesis and to have a more severe and negative reaction to chronic BA 416 
supplementation. The authors identified that the neuro-toxicity that occurred in their study was 417 
due to BA accumulation, rather than to taurine depletion (63). The finding of a neuro-toxic 418 
influence of BA accumulation is also evident in humans suffering from the rare genetic 419 
condition “hyper-beta-alalinemia”, which results in the accumulation of beta amino acids in 420 
the body (64). BA accumulation such as this is unlikely to occur in healthy humans, particularly 421 
in response to the doses commonly employed in practice, due to processes such as 422 
transamination, energy delivery (57), or incorporation into carnosine (4), and therefore is not 423 
considered a risk of supplementation. These examples do however, serve to highlight the 424 
importance of considering the broader influences of BA supplementation (e.g., the independent 425 
influence of BA per se, along with collateral effects on other elements such as taurine, histidine 426 
and carnosine), when interpreting physiological results.  427 
Side-effects experienced from BA intake in human trials 428 
Paraesthesia was the only side-effect reported during human supplementation trials. This 429 
“tingling” or “pricking” sensation of the skin occurs as a result of a histamine independent 430 
neural pathway and is most likely induced upon binding of BA to the peripheral neuronal 431 
receptor MrgprD (65). This phenomenon is generally considered to be both transient and 432 
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harmless and appears not to be a cause for concern. Indeed some athletes have reported the 433 
sensation of paraesthesia to improve their affective response to exercise (43), although other 434 
participants in the same study reported the sensation to be uncomfortable or unpleasant, 435 
demonstrating that the experience of paraesthesia, and whether it should be considered a 436 
beneficial side effect or adverse effect, is a subjective experience that is specific to the 437 
individual. Collectively, the literature indicates that the development of paraesthesia is dose-438 
related, and closely matches the extent and time to peak blood BA concentrations (4,44). Large 439 
heterogeneity in dosing studies used in longitudinal studies, along with minimal reporting of 440 
side-effects in many of the available studies precluded statistical identification of the most 441 
effective strategy to reduce the incidence of paraesthesia. However, acute studies indicated that 442 
the splitting of doses (4) or the use of sustained release capsules (44) may be an effective way 443 
to reduce the extent and/or time to peak blood BA concentration, and thus reduce or remove 444 
the occurrence and intensity of paraesthesia symptoms. Irrespective of dosing strategy used, 445 
was evidence of considerable within and between participant variability in the occurrence and 446 
intensity of paraesthesia development, and on-going investigation of the individual 447 
determinants of paraesthesia determinant would be of interest.  448 
RECOMMENDATIONS FOR RESEARCH AND PRACTICE 449 
The current investigation highlights a number of limitations and gaps in the current evidence 450 
base related to theoretical risks and physiological consequences of BA supplementation. 451 
Collectively, the assessment and reporting of side-effects in human studies were sub-optimal, 452 
thus limiting conclusions that can be drawn, and potentially causing an under-estimation of 453 
lower level side-effects experienced. Reliance on participant self-report is ill-advised, and it is 454 
stressed that researchers should, in future, employ pre-defined, systematic and objective means 455 
of side-effect assessment and reporting. Additionally, evidence of compliance to dosing 456 
protocols, including the spacing and timing of dosing throughout the day, is important to 457 
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identify whether or not strategies to reduce the occurrence of paraesthesia are effective.  While 458 
no significant changes to any health-related biomarkers were identified in any of the individual 459 
studies that provided this data, statistical meta-analysis identified a main effect of BA 460 
supplementation on ALT, along with a trend toward increased ALP, although these markers 461 
remained well within clinical reference ranges. We suggest that further research should 462 
measure these markers, thus adding to the evidence base available. It is important to 463 
acknowledge that relatively limited data related to the influence of BA supplementation on 464 
taurine and histidine in humans is currently available, and it is possible that the available data-465 
set may have been insufficient to allow detection of small changes. It is recommended that 466 
measurements of taurine and histidine, in addition to carnosine, are included in future studies. 467 
In recognition of the considerable individual variability in response to most sports nutrition 468 
based interventions, consideration of the individual response of participants to these parameters 469 
would be of interest (66). Additionally, over-simplistic interpretations of the physiological 470 
relevance of any observed changes should be avoided. Too often minimal nutrient or biomarker 471 
changes are dichotomously interpreted as being positive, or negative, which fails to 472 
acknowledge the complexity and interaction of these processes. Changes to the tissue content 473 
of these elements should be interpreted within the context of measured changes to relevant 474 
clinical or functional outcomes. In the absence of this information, findings should be neutrally 475 
interpreted and non-evidence-based speculations related to physiological consequences 476 
avoided.  477 
DOSING RECOMMENDATIONS FOR HEALTHY HUMANS  478 
According to the recommendations of the safety evaluation model used, if no data are available 479 
to establish adverse effects in humans, then a safe upper level of intake (UL) cannot be 480 
identified. This was the case within the current risk assessment, and so the highest observed 481 
limit with sufficient evidence of safety was used to guide recommendations. Recently, two 482 
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studies have been conducted using a dosing strategy of 12g.day-1 for a period of 7 (67) or 14 483 
days (51), and no adverse effects were reported. Given the short follow-up of these studies, we 484 
recommend that intakes of 12g.day-1 should not yet be employed in general practice, pending 485 
further research. Intakes up to 6.4 g.day-1 were commonly used in the studies included within 486 
this review, and it is recommended that this intake should be adopted as the current highest 487 
observed limit (HOL) with sufficient evidence of safety. No evidence of adverse effects have 488 
been reported when doses at this level are consumed for up to 24 weeks (39). Importantly, 489 
much of the evidence described in the current risk assessment was conducted recently, with 490 
95% of human studies published within the last 10 years. Should research continue at its current 491 
rate, it is likely that knowledge of the mechanistic actions and ergogenic and therapeutic 492 
potential of BA supplementation will substantially expand in the coming years. We recommend 493 
that information presented herein is continually updated based on emerging evidence, ensuring 494 
that dosing recommendations are made in accordance with the best quality and most recent 495 
evidence available.  496 
SUMMARY AND CONCLUSIONS 497 
The current comprehensive risk assessment of human and animal data revealed no adverse 498 
effects of BA supplementation in healthy humans, within the doses and durations described. 499 
Paraesthesia was the only reported side-effect, and no evidence exists to indicate that this 500 
phenomenon has any adverse consequences. Considerable within and between participant 501 
variability exists in relation to both the frequency and intensity of paraesthesia, although 502 
strategies to slow BA absorption, thus reducing the extent and time to peak plasma BA, can be 503 
used to reduce its occurrence and intensity. Although BA supplementation in high doses was 504 
shown to reduce tissue taurine content in animal models, the available human data showed no 505 
observable effect of BA supplementation on taurine, nor on muscle histidine. Collectively, the 506 
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available evidence indicates that BA supplementation, within the doses and durations described 507 
herein, is safe for human consumption.  508 
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Table 1: Health-related biomarker response to BA supplementation 737 
Marker ES (95% Crl) Tau (50% Crl) Marker ES (95% Crl) Tau (50% Crl) 
Albumin -0.257 (-0.642, 0.130) 0.551 (0.420, 0.651) MCH 0.078 (-0.248, 0.397) 0.205 (0.074, 0.283) 
ALP 0.434 (-0.067, 0.811) 0.462 (0.325, 0.574) MCHC 0.153 (-0.242, 0.512) 0.298 (0.129, 0.407) 
ALT 0.274 (0.04, 0.527) 0.187 (0.08, 0.262) MCV  0.014 (-0.291, 0.323) 0.189 (0.066, 0.262) 
AST 0.056 (-0.74, 0.283) 0.207 (0.09, 0.292) Monocytes  0.398 (-0.685, 1.479) 1.214 (0.765, 1.487) 
Basophils 0.265 (-0.427, 0.946) 0.670 (0.390, 0.845) Neutrophils -0.400 (-0.820, 
0.022) 
0.288 (0.104, 0.394) 
Bicarbonate -0.116 (-1.241, 1.061) 0.817 (0.210, 0.971) Platelets  -0.085 (-0.266, 
0.101) 
0.101 (0.040, 0.142) 
CK -0.165 (-0.537, 0.206) 0.270 (0.107, 0.372) Potassium -0.513 (-1.183, 
0.250) 
0.609 (0.299, 0.774) 
Creatinine -0.028 (-0.226, 0.173) 0.152 (0.057, 0.220) RBC -0.043 (-0.354, 
0.265) 
0.181 (0.066, 0.248) 
Eosinophils -0.080 (-1.745, 1.591) 2.357 (1.621, 2.785) RDW -0.053 (-0.584, 
0.469) 
0.325 (0.088. 0.398) 
GFR 0.048 (-0.256, 0.346) 0.181 (0.063, 0.252) Sodium 0.497 (-0.033, 1.063) 0.392 (0.132, 0.511) 
Globulin -0.028 (-0.265, 0.196) 0.153 (0.063, 0.214) Total Bilirubin -0.285 (-0.800, 
0.212) 
0.442 (0.232, 0.571) 
Hematocrit 0.075 (-0.224, 0.375) 0.166 (0.060, 0.227) Total Protein 0.066 (-0.186, 0.327) 0.209 (0.095, 0.292) 
32 
 
 
 
Hemoglobin 0.058 (-0.288, 0.392) 0.180 (0.057, 0.246) Urea 0.178 (-0.881, 1.193) 0.861 (0.364, 1.064) 
LDH 0.018 (-0.292, 0.335) 0.237 (0.094, 0.330) Uric Acid -0.110 (-0.410, 
0.205) 
0.209 (0.078, 0.291) 
Lymphocytes 0.022 (-0.478, 0.507) 0.394 (0.168, 0.530) WBC -0.220 (-0.545, 
0.093) 
0.199 (0.072, 0.277) 
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate transaminase; CK: Creatine Kinase; GFR: Glomerular Filtration 738 
Rate; LDH: Lactate dehydrogenase;  MCH: Mean corpuscular haemoglobin; MCHC: Mean corpuscular haemoglobin concentration; MCV: 739 
Mean cell volume; RBC: Red blood cell; RDW: Red cell distribution width; WBC: White blood cell.   740 
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FIGURE CAPTIONS:  741 
Figure 1: Search Flow Diagram 742 
Figure 2: GRADE quality rating of outcomes from longitudinal (Panel A) and acute (Panel 743 
B) trials 744 
Figure 3: Forest plot displaying the influence of BA supplementation on taurine in humans.  745 
Figure 4: Forest plot displaying the influence of BA supplementation (<3% in drinking 746 
water) on taurine in murine cardiac or skeletal muscle. 747 
Figure 5: Forest plot displaying the influence of BA supplementation (≥3% in drinking 748 
water) on taurine in murine cardiac or skeletal muscle. 749 
 750 
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Supplemental Table 1: Evidence from human longitudinal studies 
Author 
(date) 
Aim  Population (n) Dosing Strategy (total dose) Primary Outcome  
Al Horani et 
al. (2017) (1) 
To investigate if BA 
supplementation impacts 
anaerobic capacity parameters 
during a Wingate test.  
Healthy and physically active, but non-
specifically trained males (10) and females (6) 
aged 32.2 ± 4.8 yrs (BA: 8 (5M, 3F); PLA: 8 
(5M, 3F)) 
7 day protocol comprising 5 g.day-1, 
with participants given the choice of 
dividing this into 2 or 3 daily doses 
(Total BA: 35g) 
No information provided 
Allman et al. 
(2018) (2) 
To investigate the influence of BA 
supplementation on physical 
performance and quality of life in 
individuals who have parkinsons 
disease.  
Men (13) and women (6) with Parkinsons 
disease, aged 68 ± 9 yrs (BA n = 9; PLA n = 
10).  
28 day protocol, comprising 4.8 
g.day-1 provided as 3 daily doses 
(Total BA: 134.4 g) 
No side-effects were reported.  
Baguet et al. 
(2009) (3) 
To investigate the magnitude of 
carnosine loading in response to 
β-alanine and the time course of 
subsequent unloading in different 
human skeletal muscle types. 
Physically active but non-specifically trained 
males aged 22.6 ± 1.9 (BA: 8, PLA: 7)  
35 - 42 day protocol, comprising 
2.4g.day-1 for 2 days, 3.6g.day-1 for 2 
days, then 4.8 g.day-1 for the 
remaining 31 - 38 days, provided as 6 
daily doses (Total BA: 160.8 - 
194.4g).  
No side-effects reported.  
Baguet et al. 
(2010) (4) 
To investigate if β-alanine is 
ergogenic for a 2000m rowing 
test. 
Elite Belgian rowers, competing at national or 
international level, (comprising 18 males and 1 
female) aged 24.2 ± 5  (BA: 8 PLA: 9) 
49 day protocol, comprising 5g.day-1 
of BA, provided as 5 daily doses 
(Total BA: 245g).  
No side-effects reported.  
Baguet et al. 
(2010) (5) 
To investigate if  β-alanine 
supplementation can attenuate 
exercise-induced acidosis during 
high-intensity exercise. 
Physically active but non-specifically trained 
males aged 21.5 ± 1.2 (BA: 7; PLA: 7) 
28 day protocol, comprising 2.4 
g.day-1 for 2 days, 3.6g.day-1 for 2 
days, then 4.8g.day-1 for the 
remaining 24 days, provided as 6 
daily doses (Total BA: 127.2).  
No information provided 
Bailey et al. 
(2018) (6) 
To investigate the combined 
influence of BA supplementation 
and endurance training on 
anthropometric measures and 
physical function in older adults.  
Older, healthy men and women aged 67.8 ± 6.7 
yrs yrs, who were living independently (BA n = 
13, PLA n = 14) 
84 day protocol, comprising 3.2g.day-
1, provided as 2 daily doses in 
sustained release tablets (Total BA: 
268.8g) 
No information provided.  
Bassinello et 
al. (2018) (7) 
To investigate the influence of BA 
supplementation on isotonic, 
isometric and isokinetic muscular 
endurance tests.  
Young, healthy, omnivorous and resistance-
trained men aged 24.5 ± 4  yrs (BA n = 9, PLA 
n = 11).  
28 day protocol, comprising 6.4 
g.day-1, provided as 4 daily doses in 
sustained release capsules (Total BA: 
179.2 g) 
No information provided.  
Bech et al. 
(2017) (8) 
To investigate the effect of BA on 
fatigue development during a 
Elite male (10) and female (7) kayak rowers, 
competing at national and international level, 
56 day protocol, comprising 
80.mg.kg.day-1, provided as 3 daily 
One male participant in the 
BA group experienced mild 
Supplementary Data 
maximal voluntary contraction, a 
2-min MVC and on kayak 
ergometer and repeated sprint 
performance (5 x 250 m kayak).  
aged 21.4 ± 2.7 yrs (BA: 9; PLA: 8)  doses and using slow release capsules 
(Total BA: 392g) 
paresthesia during the first 
week of the supplementation 
period.  
Bellinger and 
Minahan 
(2016a) (9) 
To investigate the effects of β-
alanine supplementation, alone, or 
in combination with sprint interval 
training, on cycling performance.  
Endurance trained male cyclists, aged 25.4 ± 7.2 
(BA: 7; PLA: 7) 
28 day protocol, comprising 6.4g.day-
1, provided as 4 daily doses followed 
by 1.2 g.day-1 maintenance for 5 
weeks during training. (Total BA: 
221.2g). 
No side-effects reported.  
Bellinger and 
Minahan 
(2016b) (10) 
To investigate the metabolic 
consequences of β-alanine 
supplementation during 
exhaustive supramaximal cycling 
and 4000m cycling time trial 
performance. 
Trained male cyclists, aged 24.5 ± 6.2 yrs (BA: 
9; PLA: 8) 
28 day protocol, comprising 6.4g.day-
1, provided as 4 daily doses (Total 
BA: 179.2g). 
No information provided 
Bellinger and 
Minahan 
(2016c) (11) 
To investigate the effect of β-
alanine supplementation on 
performance in cycling time trials 
of different lengths (1, 4 & 10-
km).   
Trained male cyclists, aged 24.8 ± 6.7 yrs (BA: 
7; PLA: 7) 
28 day protocol, comprising 6.4g.day-
1, provided as 4 daily doses (Total 
BA: 179.2g).  
One participant reported mild 
symptoms of paresthesia.  
Bellinger et 
al. (2012) 
(12) 
To investigate the effect of β-
alanine supplementation alone, or 
in combination with sodium 
bicarbonate, on high intensity 
cycling performance.   
Trained male cyclists aged 25.4 ± 7.2 yrs (BA: 
7; PLA: 7) 
28 day protocol, comprising 
65mg.kg.day-1, provided as 4 daily 
doses (Total BA: 128.8g).  
Two participants who took 
BA reported mild symptoms 
of paresthesia. 
Belviranli et 
al. (2016) 
(13) 
To investigate the effect of β-
alanine supplementation alone, or 
in combination with creatine on 
oxidant and antioxidant status 
during high-intensity cycling.  
Sedentary, but otherwise healthy men aged 21.7 
± 1.9 yrs (BA: 11; PLA: 11) 
28 day protocol, comprising 3.2 
g.day-1 for 22 days, provided as two 
daily doses, followed by 6.4g.day-1 
for 6 days, provided as 4 daily doses 
(Total BA: 108.8g).  
No information provided 
Bex et al. 
(2014) (14) 
To investigate the effect of β-
alanine on muscle carnosine 
content in different limbs, and in 
trained and untrained individuals.  
Healthy non-athletes (10), road cyclists (10), 
swimmers (10) and flat water kayakers (5), aged 
22  ± 1 yrs (BA: 35) 
23 day protocol, comprising 6.4 
g.day-1 provided as 4 daily doses 
(Total BA: 147.2g). 
No side-effects reported.  
Bex et al. 
(2015) (15) 
To investigate if high volume 
and/or high intensity training can 
improve BA induced carnosine 
loading.  
Healthy, non-specifically trained males (28) 
aged 21.78 ± 1.9 yrs, all of whom took the BA 
supplement.  
23 day protocol, comprising 6.4 
g.day-1 provided as 4 daily doses and 
using slow release capsules (Total 
BA: 147.2g). 
No side-effects reported.  
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Black et al. 
(2018) (16) 
To investigate the influence of BA 
supplementation on muscle 
carnosine, muscle pH and the 
power-duration relationship.  
Healthy male subjects aged 22 ± 3 yrs (BA n = 
10, PLA n = 10).  
28 day protocol, comprising 6.4 
g.day-1, provided as 4 daily doses in 
sustained release tablets (Total BA: 
179.2g)   
No subject reported any 
adverse effect of 
supplementation.  
Blanquaert et 
al. (2017) 
(17) 
To investigate the independent 
and combined effects of BA and 
histidine supplementation on 
carnosine loading.  
Healthy, non-specifically trained males (15) and 
females (15) aged 20 ± 2.4 yrs (BA: 10; HIS: 
10; BA + HIS: 10) . 5M and 5F in each group. 
23 day protocol, comprising 6g.day-1 
of BA or 4.7g.day-1 of HIS or a 
combination of both supplements, all 
of which were provided as 6 daily 
doses (Total BA: 138g).  
No information provided. 
Brisola et al. 
(2016) (18) 
To investigate the effect of β-
alanine supplementation on 
repeated sprint ability in water 
polo players. 
Well-trained male water polo athletes, aged 18 
± 4 (BA: 11; PLA: 11) 
28 day protocol, comprising 4.6 
g.day-1 for 10 days, provided as 6 
daily doses, followed by 6.4 g.day-1 
for 18 days, provided as 4 daily doses 
(Total BA: 163.2g).  
3 participants in the β-A group 
and 1 in the placebo group 
reported paresthesia.  
Brisola et al. 
(2018) (19) 
To investigate the influence of BA 
supplementation on distance 
covered, time in different speed 
zones and sprint numbers during a 
simulated water polo game.  
Young, male, well-trained water polo athletes, 
aged 16 ± 1 yrs (BA n = 6, PLA n = 5).  
28 day protocol, with the first 10 days 
comprising 4.8 g.day-1 provided as 6 
daily doses, followed by 18 days of 
6.4 g.day-1, provided as 4 daily doses 
in sustained release capsules (Total 
BA: 163.2g) 
No information provided.  
Carpentier et 
al. (2015) 
(20) 
To investigate the effect of β-
alanine supplementation, in 
combination with high intensity 
training on strength and 
plyometric performance.   
Healthy, physically active male (12) and female 
(15) physical education students, aged 21.7 ± 
2.1 (BA: 14, 6 M, 8 F; PLA: 13, 6M 7F) 
56 day protocol, comprising 5.6 
g.day-1 provided as 7 daily doses 
(Total BA: 313.6g).  
No side-effects reported. 
Caruso et al. 
(2014) (21) 
To investigate the effect of β-
alanine supplementation on 
response to supramaximal lower 
body exercise performance.   
Healthy, untrained college aged males (6) and 
females (4),  (BA: 10; PLA: 10) 
30 day protocol, comprising 3g.day-1, 
provided as 5 daily doses (Total BA: 
90g).  
No side-effects reported.  
Carvalho et 
al. (2018) 
(22) 
To investigate the influence of 
exercise and BA supplementation 
on carnosine-aldehyde adducts.  
Male cyclists aged 36 ± 6 yrs (BA n = 14, PLA 
n = 14).  
28 day protocol, comprising 6.4 
g.day-1 provided as 4 daily doses in 
sustained release capsules (Total BA: 
179.2g) 
No information provided.  
Chung et al. 
(2012) (23) 
To investigate the effect of  β-
alanine supplementation on 
swimming training and 
competition performance.  
Elite/sub-elite swimmers (34 men and 26 
females), representing all competitive strokes 
and distances, aged 21.7 ± 2.8 (BA: 22; PLA: 
12)  
28 day protocol, comprising 4.8 
g.day-1 for 28 days provided as 3 
daily doses, followed by 3.2g.day-1 
provided as 2 daily doses for  42 days 
(Total BA: 268.8g).  
10 of the 22 respondents from 
the β-A group reported mild 
paresthesia.  
Supplementary Data 
Chung et al. 
(2014) (24) 
To investigate the effect of  β-
alanine supplementation on 
cycling time trial performance.  
Well trained male cyclists/triathletes, aged 30.9 
± 7.7 (BA: 14; PLA: 13) 
42 day protocol, comprising 6.4g.day-
1, provided as 4 daily doses (Total 
BA: 268.8g).  
No side-effects reported.  
Church et al. 
(2017) (25) 
To compare 6 and 12 g.day-1 for 
28 and 14 days on changes in 
carnosine, histidine and BA in 
both muscle and plasma.  
Physically active males (18) and females (12) 
aged 23.77 ± 3 yrs (BA: 17; PLA: 8) . 
28 day protocol of 6 g.day-1 or 14 
days of 12 g.day-1 of BA, provided as 
3 x 2g or 3 x 4 g daily doses (Total 
BA: 168g).   
Paresthesia was the only side-
effect reported, and the 
number of individuals 
reporting did not differ 
between the groups (p = 
0.483), namely 1 participant in 
PLA; 3 in the 6g group and 2 
in the 12g group.  
Claus et al. 
(2016) (26) 
To investigate the effect of  β-
alanine supplementation on water 
polo specific tests.  
Trained, post-pubertal water polo players, aged 
16 ± 2 (BA: 8; PLA: 7) 
42 day protocol, comprising 6.4g.day-
1, provided as 4 daily doses (Total 
BA: 268.8g).  
No information provided 
Cochran et 
al. (2015) 
(27) 
To investigate the effect of  β-
alanine on sprint interval training 
induced skeletal muscle 
adaptation and performance.   
Physically active, but non-specifically trained 
males, aged 22.5 ± 2 (BA: 12; PLA: 12) 
70 day protocol, comprising 3.2g.day-
1 provided as two daily doses via 
slow release tablets (Total BA: 224g). 
No information provided 
Da Silva et 
al. (2018) 
(28) 
To investigate the influence of BA 
supplementation on bioenergetic 
contribution during high intensity 
intermittent exercise, and on 
cycling time-trial (1km) 
performance.  
Trained cyclists aged 38 ± 8.1 yrs (BA n = 36, 
PLA n = 35) 
28 day protocol, comprising 6.4 
g.day-1 provided as 4 daily doses in 
sustained release capsules (Total BA: 
179.2g) 
Three volunteers reported 
paresthesia with BA.  
Danaher et 
al. (2014) 
(29) 
To investigate the effect of the of 
β-alanine supplementation alone, 
or in combination with sodium 
bicarbonate on high intensity 
exercise performance. 
Recreationally active males, aged 26.2 ± 1.9 yrs, 
(BA: 8; PLA: 8) 
42 day protocol, comprising 4.8g.day-
1 for 28 days, provided as 6 daily 
doses, followed by 6.4 g.day-1 for 14 
days provided as 8 daily doses (Total 
BA: 224g).  
No information provided 
Del Favero et 
al. (2012) 
(30) 
To investigate the effects of  β-
alanine supplementation on 
muscle carnosine content and 
exercise capacity in elderly 
subjects. 
Older adults, who were not engaged in an 
exercise program, aged 64.7 ± 5 (BA: 12; PLA: 
6) 
84 day protocol, comprising 3.2g.day-
1 provided as 2 daily doses in slow 
release capsules (Total BA: 268.8g). 
No side-effects reported.  
Derave et al. 
(2007) (31) 
To investigate the effect of  β-
alanine supplementation on sprint 
fatigue and performance.   
Well-trained male track and field athletes, aged 
21.3 ± 4.2 (BA: 8; PLA: 7) 
28-35 day protocol, comprising 
2.4g.day-1 for 4 days, followed by 
3.6g.day-1 for 4 days, then 4.8g.day-1 
for the remaining 20-27 days, 
No side-effects reported.  
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provided as 6 daily doses (Total BA: 
120 - 153.6g).  
Donovan et 
al. (2012) 
(32) 
To investigate the effect of  β-
alanine supplementation on 
boxing punch performance.  
Amateur, competitive boxers, aged 25 ± 4 yrs 
(BA: 8; PLA: 8) 
28 day protocol, comprising 6g.day-1 
provided as 4 daily doses (Total BA: 
168g) 
No side-effects reported. 
Ducker et al. 
(2013a) (33) 
To investigate the effect of  β-
alanine supplementatino on 800-m 
track running performance. 
Trained, recreational club runners, aged 22 ± 
5.4 (BA: 9; PLA: 9)  
28 day protocol, comprising 
80mg.kg.day-1 provided as 4 daily 
doses (Total BA: 162.4).  
No information provided 
Ducker et al. 
(2013b) (34) 
To investigate the effect of  β-
alanine supplementation, alone or 
in combination with sodium 
bicarbonate on repeated sprint 
performance.  
Competitive intermittent team sport male 
athletes aged 21 ± 4.5 (BA: 6; PLA: 6) 
28 day protocol, comprising 
80mg.kg.day-1 provided as 4 daily 
doses via slow release capsules (Total 
BA: 187.6g).  
No information provided 
Ducker et al. 
(2013c) (35) 
To investigate the effect of  β-
alanine supplementation on 2,000-
m rowing ergometer performance. 
Competitive male rowers aged 26 ± 9 (BA: 7; 
PLA: 9) 
28 day protocol, comprising 
80mg.kg.day-1 provided as 4 daily 
doses via slow release capsules (Total 
BA:187.6g).  
No information provided 
Ghiasvand et 
al. (2012) 
(36) 
To investigate the effects of β-
alanine supplementation on 
endurance performance.  
Physically active male physical education 
students, aged 21.5 ± 5.1 (BA: 20; PLA: 19) 
42 day protocol, comprising 2g.day-1 
provided as 5 daily doses (Total BA: 
84g).  
No side-effects reported.  
Eilaki et al. 
(2018) (37) 
To investigate the influence of BA 
supplementation on ventilatory 
thresholds.  
Male amateur swimmers aged 31.5 ± 8  (BA n = 
6, PLA n = 8).  
14 day protocol, comprising 2.3 
g.day-1 for 7 days, followed by 4.6 
g.day-1 for 7 days, provided as 2 daily 
doses (Total BA: 48.3g) 
No information provided  
Furst et al. 
(2018) (38) 
To investigate the influence of BA 
supplementation on exercise 
endurance and executive function.  
Middle aged, healthy and non-specifically 
trained men (8) and postmenopausal women (4) 
aged 60.5 ±  8.6 yrs (BA n = 7, PLA n = 5) 
28 day protocol, comprising 2.4 
g.day-1 provided as 3 daily doses 
(Total BA: 67.2g) 
There were no subject 
complaints of paresthesia.  
Glenn et 
al.(2015a) 
(39) 
To investigate the effects of  β-
alanine on high intensity cycling 
performance.   
Trained female masters cyclists, aged 53.3 ± 1 
(BA: 11; PLA: 11) 
28 day protocol, comprising 3.2g.day-
1 provided as 4 daily doses (Total 
BA: 89.6g).  
One subject reported feelings 
of paresthesia.  
Greer et al. 
(2016) (40) 
To investigate the effect of  β-
alanine supplementation on 
endurance performance.  
Aerobically trained males aged 28.8 ± 9.8 yrs 
(BA: 7; PLA: 7) 
30 day protocol, comprising 3g.day-1 
for 7 days, followed by 6g.day-1 for 
23 days, all provided as 4 daily doses 
(Total BA: 159g).  
One participant reported 
paresthesia, but they were in 
the placebo group.  
Gross et al. 
(2014a) (41) 
To investigate the effect of  β-
alanine on high intensity and 
plyometric performance.  
Elite male alpine skiiers, aged 19.5 ± 1.1 (BA: 
5; PLA: 4) 
35 day protocol comprising 4.8g.day-1 
provided as three daily doses (Total 
BA: 168g).  
Four out of the 5 subjects 
receiving BA reported no side 
effects. One participant 
reported having frequent and 
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severe paresthesia as well as 
some digestion problems.  
Gross et 
al.(2014b) 
(42) 
To investigate the effects of  β-
alanine supplementation and HIT 
on high intensity exercise 
performance.   
Male athletes, competing in endurance, team or 
combat sports, aged 31 ± 8 (BA: 6; PLA: 9) 
38 day protocol, comprising 3.2g.day-
1 provided as 4 daily doses (Total 
BA: 121.6g).  
No information provided 
Hannah et 
al. (2015) 
(43) 
To investigate the effect of  β-
alanine supplementation on in 
vivo contractile properties and 
voluntary neuromuscular 
performance. 
Moderately active, but non-specifically trained 
males, aged 25.8 ± 6.4 (BA: 12; PLA: 11) 
28 day protocol, comprising 6.4g.day-
1, provided as 4 daily doses via slow 
release capsules (179.2g).  
No side-effects reported.  
Harris et al. 
(2006) (44) 
To investigate the bioavailability 
of oral  β-alanine supplementation 
and its effect on muscle carnosine 
synthesis. 
      
PART B To investigate the effect of 2 
weeks of β-alanine intake.  
Male subjects, aged 28.3 ± 2.7 yrs (BA: 6) 14 day protocol, comprising 
30mg.kgBM.day-1, provided as 3 
daily doses (Total BA:34.3g).  
Occasional reports of mild 
flushing were reported.  
PART C To investigate the effect of 4 
weeks β-alanine supplementation 
on blood biochemistry and 
haematology.  
Male subjects, aged 19.4 ± 1.6 yrs (BA: 8; PLA: 
8) 
28 day protocol, comprising 3.2g.day-
1 provided as 4 daily doses (Total 
BA:89.6g).  
No information provided.  
PART D To investigate the effect of 4 
weeks β-alanine supplementatino 
on muscle carnosine content.  
Male subjects aged 26.1 ± 5.6 yrs (21 total; 10 
BA, 5 CARN, 6 PLA)  
Treatment 1: 28 day protocol 
comprising 3.2g.day-1 provided as 4 
daily doses (Total BA:89.6g). 
Treatment 2: 28 day protocol 
comprising 4g.day-1 for the first 
week, with doses increasing each 
week so that in week 4 participants 
ingested 6.4g.day-1, all provided as 8 
daily doses (Total BA: 145.6g). 
Treatment 3:  Equal to T2, however 
β-A was provided in the form of L-
carnosine (Total BA: 143.3g). 
Treatment 4: placebo.  
Mild symptoms of flushing 
were reported in week 2 by 4 
of the subjects given BA, 
while one subject given 
placebo also recorded mild 
symptoms of flushing.  
Hill et 
al.(2007) (45) 
To investigate the effect of  β-
alanine supplementation on high 
intensity  cycling capacity. 
Physically active, but non-specifically trained 
males, aged 27.2 ± 5.3 (4 weeks - BA: 13; PLA: 
12; 10 weeks - BA: 7; PLA: 8) 
70 day protocol, comprising 4 g.day-1 
for 7 days, 4.8g.day-1 for 7 days, 
5.6g.day-1 for 7 days and 6.4g.day-1 
Reports of symptoms of 
paresthesia were infrequent 
and mild when they occurred.  
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for the final 49 days, all provided as 8 
daily doses (Total BA: 4 weeks: 
145.6g; 10 weeks: 414.4g) 
Hobson et 
al.(2013) (46) 
To investigate the effect of  β-
alanine alone, or in combination 
with sodium bicarbonate on 
2000m rowing performance. 
Trained, competitive club level rowers aged 23 
± 4 (BA: 10; PLA: 10) 
30 day protocol, comprising 6.4g.day-
1 provided as 4 daily doses via slow 
release capsules (Total BA: 192g).  
No side-effects reported.  
Hobson et al. 
(2014) (47) 
To investigate the effect of  β-
alanine on 20km time trial 
performance. 
Well-trained male cyclists aged 33.7 ± 7, (BA: 
10; PLA: 9) 
28 day protocol, comprising 6.4g.day-
1 provided as 4 daily doses via slow 
release capsules (Total BA: 179.2g).  
No side-effects reported.  
Hoffman et 
al. (2008a) 
(48) 
To investigate the effect of  β-
alanine supplementation on 
resistance training volume and the 
acute endocrine response to 
resistance exercise. 
Resistance trained males aged 19.7 ± 1.5yrs 
(BA: 8; PLA: 8) 
28 day protocol comprising 4.8g.day-1 
provided as 3 daily doses (Total BA: 
134.4g).  
No information provided 
Hoffman et 
al. (2008b) 
(49) 
To investigate the effect of  β-
alanine supplementation on 
training volume and anaerobic 
exercise performance.  
Strenth/power trained male athletes, aged 19.8 ± 
1.6 (BA: 13; PLA: 13) 
30 day protocol comprising 4.5g.day-1 
provided as 3 daily doses (Total BA: 
135g).  
No information provided 
Hoffman et 
al. (2014) 
(50) 
To investigate the effect of  β-
alanine supplementation on 
physical and cognitive 
performance.  
Male soldiers from an elite combat unit of the 
Israel Defense Forces aged 20.2 ± 0.9 (BA: 9; 
PLA: 9) 
28 day protocol comprising 6g.day-1 
provided as 3 daily doses (Total BA: 
168g).  
4 participants in the β-A group 
reported isolated incidences of 
paresthesia. No other adverse 
events were reported for any 
other participant. 
Hoffman et 
al.(2015) (51) 
To investigate the effect of  β-
alanine supplementation on 
combat specific activity.   
Male soldiers from an elite combat unit of the 
Israel Defense Forces aged 19.9 ± 0.8 (BA: 9; 
PLA: 9) 
30 day protocol comprising 6g.day-1 
provided as 3 daily doses (Total BA: 
180g).  
No side-effects reported.  
Hoffman et 
al. (2018) 
(52) 
To investigate the influence of BA 
supplementation on anti-
inflammatory cytokines during 
intense military training.  
Male soldiers from an Israel Defence Force elite 
combat unit, aged 20.1 ±  0.6 yrs (BA n = 10, 
PLA n = 10).  
7 day protocol comprising 12 g.day-1, 
provided as 3 daily doses in sustained 
release capsules (Total BA: 84g) 
Of those participants who 
were excluded from final 
analyses for non-compliance, 
one experienced side effects 
(itching and flushing).  
Howe et 
al.(2013) (53) 
To investigate the effect of  β-
alanine supplementation on 4 min 
maximal cycling performance and 
isokinetic knee-extension.  
Highly trained male cyclists aged 24 ± 6.8 (BA: 
8; PLA: 8) 
28 day protocol comprising 
65mg.kg.day-1 provided as 4 daily 
doses (Total BA:  127.4g) 
2 participants in the β-A group 
reported paresthesia. 
Jagim et 
al.(2013) (54) 
To investigate the effect of  β-
alanine supplementation on sprint 
Trained men comprising wrestlers (11), 
recreationally strength trained athletes (6) and 
35 day protocol comprising 4g.day-1 
for 7 days followed by 6g.day-1 for 
No information provided 
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endurance at two different 
supramaximal intensities. 
rugby players (4) aged 20 ± 2.3 (BA: 10; PLA: 
11) 
the remaining 28 days, all provided 
as 3 daily doses (Total BA: 196g) .  
Jones et al. 
(2017) (55) 
To investigate the effect of  β-
alanine supplementation on knee 
extensor force production and 
muscle contractility in fresh and 
fatigued human muscle, during 
voluntary and electrically evoked 
contractions.  
Non-specifically trained males aged 22 ± 1.5 
(BA: 12; PLA: 11) 
28 day protocol comprising 6.4g.day-1 
provided as 4 daily doses (Total BA: 
179.2g).  
No side-effects reported.  
Jordan et 
al.(2010) (56) 
To investigate the effect of  β-
alanine supplementation on the 
onset of blood lactate 
accumulation (OBLA) during 
incremental treadmill running. 
Recreationally active runners aged 24.9 ± 4.5 
(BA: 8; PLA: 9) 
28 day protocol, comprising 6g.day-1 
provided as 3 daily doses (Total BA: 
168g).  
3 participants in the β-A group 
reported  tingling in their 
fingers and hands 
(paresthesia).  
Kendrick et 
al. (2008) 
(57)  
To investigate the effect of  β-
alanine supplementation on 
training induced resistance 
responses.  
Fit and healthy non-resistance trained physical 
education students aged 21.5 ± 2 (BA: 13; PLA: 
13) 
28 day protocol comprising 6.4g.day-1 
provided as 8 daily doses (Total BA: 
179.2g).  
No information provided 
Kendrick et 
al. (2009) 
(58) 
To investigate the effect of 
isolateral training with, and 
without β-alanine supplementation 
on muscle carnosine content.  
Fit and healthy physical education students aged 
21.9 ± 2.6 (BA: 7; PLA: 7) 
28 day protocol comprising 6.4g.day-1 
provided as 8 daily doses (Total BA: 
179.2g).  
No information provided 
Kern and 
Robinson. 
(2011) (59) 
To investigate the effect of β-
alanine supplementation with high 
intensity training  on anaerobic 
power and body composition.   
NCAA division II college wrestlers and 
American Footballers aged 19.4 ± 1.8. (BA: 17; 
PLA: 20) 
56 day protocol comprising 4g.day-1 
provided as 2 daily doses (Total BA: 
224g).  
No information provided 
Kratz et al. 
(2016) (60) 
To investigate the effect of β-
alanine supplementation on judo 
performance.  
Well-trained male judo competitors aged 17.9 ± 
2.7 (BA: 12; PLA: 11) 
28 day protocol comprising 6.4g.day-1 
provided as 4 daily doses(Total BA: 
179.2g).  
1 participant in the β-A group, 
and one in the placebo group 
reported mild paresthesia.  
Kresta et al. 
(2014) (61) 
To investigate the effect of β-
alanine supplementation only, or 
with creatine, on anaerobic 
performance.  
Healthy, moderately active females aged 
between 18 and 35 (BA only 8, PL: 7) 
28 day protocol comprising 
0.1g.kg.day-1 provided as 4 daily 
doses (Total BA: 170.8g) 
No information provided 
Mate-Munoz 
et al. (2018) 
(62) 
To investigate the influence of BA 
supplementation during a 
resistance training program on 
strength and power outcomes.  
Young, healthy, resistance-trained men aged 18 
- 25 yrs (BA n= 14, PLA n = 12) 
35 day protocol, comprising 6.4 
g.day-1 provided as 8 daily doses, 
taken alongside a resistance training 
program (Total BA: 224g) 
No information provided.  
McCormack To investigate the effect of an oral Older men  and women  aged 71.2 ± 6.3  (BA:  84 day protocol comprising 1.6 or 6 participants in the 2.4g.day-
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et al. 2013 
(63) 
nutritional supplement fortified 
with β-alanine on body 
composition, muscle function and 
physical capacity in older adults.  
(BA: 28; PLA: 16).  2.4g.day-1 provided as 2 daily doses 
with an oral nutritional supplement 
(Total BA: 134.4 - 201.6g).  
1 group, and 1 from the 
1.6g.day-1 group reported 
paresthesia. 2 of the dropouts 
from the 2.4g.day-1 group 
cited paresthesia as the reason 
for withdrawal.  
Mero et al. 
(2013) (64) 
 To investigate the effect of β-
alanine supplementation alone, or 
with sodium bicarbonate on 
maximal sprint swimming.  
National and international male swimmers aged 
20.5 ± 1.4 yrs (BA: 13) 
28 day protocol comprising 4.8g.day-1 
provided as 8 daily doses (Total BA: 
134.4).  
All participants in the β-A 
group reported paresthesia.  
Milioni et al 
(2017) (65) 
To investigate the effect of β-
alanine supplementation on 
repeated sprint ability and 
technical basketball performance.  
Post-pubertal male basketball players aged 16-
19 yrs (BA: 12; PLA: 10) 
42 day protocol comprising 6.4g.day-1 
provided as 4 daily doses (Total BA: 
268.8g).  
7 participants in the β-A 
group, and 3 in the placebo 
group reported isolated 
occurrences of mild 
paresthesia.  
Outlaw et al. 
(2016) (66) 
To investigate the effect of β-
alanine supplementation during 
resistance training on aerobic & 
anaerobic performance and body 
composition.  
Collegiate, non-specifically trained females 
aged 21 ± 2.2 yrs (BA: 7; PLA: 8).  
56 day protocol comprising a single 
dose of 3.4g.day-1 prior to training 4 
days.week-1 (Total BA: 108.8g).  
No side-effects reported.  
Painelli et al. 
(2013) (67) 
        
Part A To investigate the effect of β-
alanine supplementation on 
swimming performance 
Junior standard male (12) and female (6) 
swimmers aged 19.3 ± 4.1 (BA: 9; PLA: 7) 
35 day protocol comprising 3.2g.day-1 
for 7 days, followed by 6.4g.day-1 for 
28 days, all provided as 4 daily doses 
(Total BA: 201.6g).  
4 participants in the β-A group 
reported mild paresthesia 
Part B To investigate the co-ingestion of 
β-alanine and sodium bicarbonate 
on swimming performance.  
Junior standard male (7) and female (7) 
swimmers aged 19.7 ± 3.1 (BA: 7; PLA: 7) 
32 day protocol comprising 3.2g.day-1 
for 7 days, followed by 6.4g.day-1 for 
25 days, all provided as 4 daily doses 
(Total BA: 182.4g).  
4 participants in the β-A group 
reported mild paresthesia.  
Painelli et al. 
(2014) (68) 
To investigate the effect of β-
alanine supplementation on high 
intensity exercise performance in 
trained and non-trained cyclists.  
Endurance trained male cyclists (20) or non 
trained males aged 28.9 ± 8.3 (BA: 20; PLA: 
19) 
28 day protocol comprising 6.4g.day-1 
provided as 4 daily doses (Total BA: 
179.2g) 
3 participants in the β-A group 
reported paresthesia.  
Rosas et al. 
(2017) (69) 
To investigate the effects of a 
plyometric training program, with 
and without BA supplementationo 
on maximal intensity and 
Amateur female soccer platers (25) aged 23.7 ± 
2.4 yrs (BA: 8; PLA: 17) 
42 day protocol comprising 4.8g.day-1 
provided as 6 daily doses (Total BA: 
201.6g).  
Five athletes in the BA group 
reported mild paresthesia 
symptoms 
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endurance performance in female 
soccer players. 
Sale et 
al.(2011) (70) 
To investigate the effect of β-
alanine supplementation only, and 
with sodium bicarbonate 
supplementation on high intensity 
cycling capacity. 
Physically active males accustomed to high 
intensity exercise aged 24.5 ± 4.1 (BA: 10; 
PLA: 10)  
28 day protocol, comprising 6.4g.day-
1 provided as 4 daily doses (Total 
BA: 179.2g).  
No information provided. 
Sale et 
al.(2012) (71) 
To investigate the effect of β-
alanine supplementation on 
submaximal isometric endurance 
of the knee extensor muscles. 
Physically active males aged 23 ± 6 (BA: 7; 
PLA: 6) 
28 day protocol comprising 6.4g.day-1 
provided as 8 daily doses (Total BA: 
179.2g).  
No information provided.   
Santana et 
al. (2018) 
(72) 
To investigate the influence of BA 
supplementation on 10km running 
time trial performance.  
Healthy, male runners aged 29.4 ± 3.9 yrs  (BA 
n = 8, PLA n = 8).  
23 day protocol comprising 5g.day-1 
provided as 3 daily doses (Total BA: 
115 g) 
No information provided.  
Saunders et 
al. (2012a) 
(73) 
To investigate the effect of β-
alanine supplementation on 
multiple sprint performance 
during the Loughborough 
Intermittent Shuttle Test (LIST) 
Male elite hockey players and non-elite football 
or hockey players aged 20.7 ± 2.5 (BA: 18; 
PLA: 18)  
28 day protocol comprising 6.4g.day-1 
provided as 4 daily doses (Total BA: 
179.2g).  
No side-effects reported.  
Saunders et 
al. (2012b) 
(74) 
To investigate the effect of β-
alanine supplementation on YoYo 
intermittent recovery test level 2 
(YoYo IRL2) performance 
Amateur male footballers aged 22 ± 4 yrs (BA: 
9; PLA: 8) 
84 day protocol comprising 3.2g.day-1 
provided as 4 daily doses via slow 
release capsule (Total BA: 268.8g).   
No side-effects reported.  
Saunders et 
al. (2014) 
(75) 
To investigate the effect of β-
alanine supplementation only, or 
with sodium bicarbonate on 
repeated sprints performance in 
hypoxia. 
Recreationally active male games players aged 
22.5 ± 3.5 (BA: 8; PLA: 8)  
25 day protocol comprising 6.4g.day-1 
for 28 days, followed by 3.2g.day-1 
for 7 days, all provided as 4 daily 
doses via slow release capsules (Total 
BA: 201.6g).   
No side-effects reported.  
Saunders et 
al. (2018) 
(76) 
To investigate the effect of BA 
supplementation on muscle 
taurine, blood clinical markers and 
sensory side-effects.  
Physically active healthy males aged 27 ± 4 
(BA: 15; PLA: 8) 
168 day protocol comprising 
6.4g.day-1 provided as 4 daily doses 
(Total BA: 1075.2g).   
No side-effects reported 
Smith et al. 
(2009) (77) 
To investigate the effect of β-
alanine supplementation during 
HIIT on endurance performance 
and body composition.  
Recreationally active men aged 22.2 ± 2.7 yrs 
(BA: 18; PLA: 18) 
42 day protocol comprising 6g.day-1 
for 21 days, followed by 3g.day-1 for 
21 days (Total BA: 189g) 
No information provided.  
Smith et 
al.(2012a) 
To investigate the effect of β-
alanine supplementation on 
Moderately trained healthy women aged 21.7 ± 
2.1 (BA: 13; PLA: 11)  
28 day protocol comprising 4.8g.day-1 
provided as 3 daily doses (Total BA: 
2 participants in the β-A group 
reported mild symptoms of 
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(78) markers of oxidative stress, and 
measures of aerobic performance 
in women. 
134.4g).  paresthesia, reported as mild 
prickling on the back of the 
hands and face.  
Smith-Ryan 
et al. (2012b) 
(79) 
To investigate the effect of β-
alanine supplementation on high-
velocity intermittent running 
performance. 
Recreationally active men and women aged 21.9 
± 2.8 (BA: 26; PLA: 24) 
28 day protocol comprising 4.8g.day-1 
provided as 3 daily doses (Total BA: 
134.4g).  
2 participants in the β-A 
group, and 3 in the placebo 
group reported mild 
paresthesia. 
Smith-Ryan 
et al. (2014a) 
(80) 
To investigate the effect of β-
alanine supplementation on 
exercise induced oxidative stress 
in men. 
Recreationally active males aged 21.9 ± 3.4yrs 
(BA: 12; PLA: 13) 
28 day protocol comprising 4.8g.day-1 
provided as 3 daily doses (Total BA: 
134.4g). 
No information provided.  
Smith-Ryan 
et al.(2014b) 
(81) 
To investigate the effect of β-
alanine supplementation on 
physical working capacity at heart 
rate threshold. 
Recreationally active men and women aged 21 
± 2.1 (BA: 15; PLA: 15)  
28 day protocol comprising 6.4g.day-1 
(Total BA: 179.2g).   
No side-effects reported.  
Solis et al. 
(2015) (82) 
To investigate the effect of β-
alanine supplementation brain 
homocarnosine/carnosine levels 
and cognitive function.  
      
PART A To investigate the effect of β-
alanine supplementation on brain 
carnosine content, assessed using 
1H-MRS. 
Healthy vegetarians (3 women and 4 men) and 
age and sex matched omnivores aged 29.7 ± 8.7 
(BA: 14) 
28 day protocol comprising 6.4g.day-1 
provided as 4 daily doses  (Total BA: 
179.2g).  
No information provided 
Part B To investigate the effect of β-
alanine supplementation on 
cognitive function. 
UK category 1 male cyclists aged 34.6 ± 7.4 
(BA: 10; PLA: 9) 
28 day protocol comprising 6.4g.day-1 
provided as 4 daily doses (Total BA: 
179.2g).  
No information provided 
Stegen et al. 
(2013) (83) 
        
PART A To investigate the effect of 5-
week BA supplementation with 
and without coingestion of 
carbohydrate and protein on whole 
body BA retention.  
Men aged 22.1 ± 1.3 yrs (BA: 7) 35 day protocol comprising 4.8g.day-1 
slow release BA provided as three 
daily doses (Total BA: 168g).  
No information provided 
PART B To investigate the effect of meal 
timing on muscle carnosine 
loading.  
Men (16) and women (18) aged 19.4 ± 1 yrs 
(BA: 34).  
46 day protocol comprising 3.2g.day-1 
provided as 4 daily doses (Total BA: 
147.2g).  
No information provided 
Stellingwerf 
et al. (2012) 
To investigate the effect of two 
different doses of β-alanine on the 
Healthy male subjects, with baseline carnosine 
content >1 SD below mean Mcarn, aged 24.8 ± 
Group High-Low: 3.2g.day-1 for 28 
days, followed by 1.6g.day-1 for 28 
16.4, 11.6 and 20% of 
participants reported unusual 
Supplementary Data 
(84) time course of muscle carnosine 
loading and subsequent 8 week 
washout. 
4.5 (BA: 33) weeks.    Group Low - Low: 1.6g.day-
1 for 56 days (Total BA: 89.6 - 
134.4g).  
sensations for the placebo, 
low-low and high-low groups 
respectively, and this was not 
significantly different between 
the groups. These unusual 
symptoms were most 
frequently located in the arms 
and shoulders. The placebo 
group reported more negative 
POMS and SAI ratings than 
either treatment group.  
Stout et al. 
(2006) (85) 
To investigate the effect of β-
alanine supplementation only, or 
with creatine on physical working 
capacity at fatigue threshold. 
Men aged 24.5 ± 5.3 (BA: 12; PLA: 13) . 28 day protocol, comprising 6.4g.day-
1 for 6 days, provided as 4 daily 
doses, followed by 3.2g.day-1 for 22 
days, provided as 2 daily doses (Total 
BA: 108.8g). 
No information provided 
Stout et al. 
(2007) (86) 
To investigate the effect of β-
alanine supplementation physical 
working capacity at fatigue 
threshold and endurance 
performance.  
Women aged 27.4 ± 6.4 (BA: 11; PLA: 11) 28 day protocol, comprising 3.2g.day-
1 for 7 days, followed by 6.4g.day-1 
for 21 days, all provided as 3 daily 
doses (Total BA: 156.8g).  
No information provided 
Stout et al. 
(2008) (87) 
To investigate the effect of β-
alanine supplementation on 
physical working capacity at 
fatigue threshold in older adults.  
Community dwelling older men and women, 
aged 72.8 ± 11.1 (BA: 12; PLA: 14) 
90 day protocol, comprising 2.4g.day-
1 provided as 3 daily doses (Total 
BA: 216g).  
No information provided 
Sweeney et 
al. (2010) 
(88) 
To investigate the effect of β-
alanine supplementation on repeat 
high-intensity sprint performance. 
Physically active males, trained in either 
football or strength, aged 22.6 ± 1.5 (BA: 9; 
PLA: 10) 
35 day protocol comprising 4g.day-1 
for 7 days, followed by 6g.day-1 for 
28 days, all provided as 3 daily doses 
(Total BA: 196g).  
Subjects (number unspecified) 
reported mild paresthesia. 
Tobias et 
al.(2013) (89) 
To investigate the effect of β-
alanine supplementation only, or 
with sodium bicarbonate on high 
intensity upper body intermittent 
exercise performance. 
Well-trained male judo and jiu-jitsu athletes 
aged 26.4 ± 4.4 (BA: 10; PLA: 9).  
28 day protocol, copmrising 6.4g.day-
1, provided as 4 daily doses (Total 
BA: 179.2g).  
1 participant in the β-A group 
reported paresthesia.  
Van Thienen 
et al. (2009) 
(90) 
To investigate the effect of β-
alanine supplementation on 
cycling performance.  
Moderate to well-trained male cyclists, aged 
24.9 (range 18 - 30; BA: 9; PLA; 8) 
56 day protocol, comprising 2g.day-1 
for 14 days, followed by 3g.day-1 for 
14 days, then 4g.day-1 for the 
remaining 28 days, all provided in 
No side-effects reported.  
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500mg capsules (Total BA: 182g) .  
Varanoske et 
al. (2017) 
(91) 
To compare 28 days of BA 
supplementation in men and 
women on performance and 
muscle carnosine, histidine and 
BA 
Recreationally active males (10) and females 
(10) (BA: 12 (6M, 6F); PLA: 8 (4M, 4F)) 
28 day protocol, comprising 6g.day-1, 
provided as 3 daily doses using slow 
release capsules (Total BA: 168g).  
No information provided 
Varanoske et 
al. (2018) 
(92) 
To investigate the influence of BA 
provided as sustained (SR) or 
rapid-release (RR) fomulations on 
muscle carnosine, BA and 
histidine, and on muscle 
performance.  
Physically active men (15) and women (14) 
aged 22.7 ± 2.6 yrs (SR BA n = 12, RR BA n = 
9, PLA n = 8) 
28 day protocol, comprising 6 g.day-1 
provided as 3 daily doses, as either a 
sustained, or rapid, release 
formulation (Total BA: 168g) 
Paresthesia was the only 
reported side-effect, and 
occurred significantly more 
frequently (25.4 ± 4.8 days) in 
the RR group, than in either 
the SR (3.4  ±  8.4 days) or 
PLA groups (0.1  ± 0.4 days). 
Walter et 
al.(2010) (93) 
To investigate the effect of β-
alanine supplementation during 
HIIT on endurance performance 
and body composition.  
Healthy, recreationally active women aged 21.8 
± 3.5 (BA: 14; PLA: 19) 
42 day protocol, comprising 6g.day-1 
for 21 days provided as 4 daily doses, 
followed by 3g.day-1 for 21 days 
provided as 2 daily doses (Total BA: 
189g).  
No information provided 
Zoeller et al. 
(2007) (94) 
To investigate the effect of β-
alanine supplementation only, or 
with creatine on endurance 
performance.  
Men aged 24.5 ± 5.3 yrs (BA: 14; PLA: 13).  28 day protocol, comprising 6.4g.day-
1 for 6 days, provided as 4 daily 
doses, followed by 3.2g.day-1 for 22 
days, provided as 2 daily doses (Total 
BA: 108.8g). 
No information provided 
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Supplemental Table 2: Evidence from human acute studies  
Author (date) Aim Population (n) Dosing Strategy Primary Outcome 
Bellinger et 
al. (2016) (95) 
To investigate the 
effect of acute β-
alanine ingestion 
on paresthesia 
symptoms, mood 
and psychological 
effects.  
Well-trained male cyclists 
(8) aged 27.7 ± 5.9 years.  
30mg.kgBM-1 (approx 1.98 g of 
BA) 
β-alanine ingestion did not impact 1km cycling time trial performance. 
β-alanine caused a significant sensory response, with the sensation 
described as "tingling or pins and needles", and a trend toward 
increased vigour (p = 0.07-008). Two of the participants reported the 
sensations to be uncomforable or unpleasant. Five of the participants 
subjectively reported that paresthesia positively influenced their 
affective response to the time trial.  
Decombaz et 
al. (2012) (96) 
To investigate the 
effect of slow 
release β-alanine 
tablets on 
absorption 
kinetics and 
paresthesia.  
Healthy males (6) and 
females (5) aged 26 ± 4 
yrs.  
1.6g provided in either slow 
release tablet form, or in pure 
aqueous solution.  
Only βA in solution produced evident sensations, with the intensity 
described as "pins and needles". Sensory response globally and 
anticipatorily  paralleled that of plasma βA concentration. Paresthesia 
symptoms were influenced by the extent and time to peak plasma βA 
concentration.  
Glenn et al. 
(2015) (97) 
To investigate the 
effect of acute β-
alanine ingestion 
on anaerobic 
performance in 
trained female 
cyclists.  
Trained competitive 
female cyclists (12) aged 
26.6 ± 1.3 yrs.  
1.6g + 34 g dextrose mixed with 
16 ounces of water. Ingested 30 
min prior to exercise.  
One participant reported feelings of paraesthesia. Anaerobic 
performance was not impacted by supplementation, but the  β-alanine 
reported lower perceived exertion during the repeated Wingate test.   
Harris et al. 
(2006) (44) 
To investigate the 
effect of acute 
administration of 
different forms of 
β-alanine on 
blood and urine 
bioavailability.   
Healthy males (6) aged 
33.5 ± 9.9 yrs.   
0, 10, 20 or 40 mg.kgBM-1, 
provided as chicken broth, or as 
pure β-alanine dissolved in water.  
Pure β-alanine caused an "irritation of the skin or a prickly sensation", 
but chicken broth did not.  This response was dose-dependent, with 
40mg.kgBM-1 causing sensations that were considered unpleasant by 
all participants, and intolerable by 2, while the lower doses invoked 
similar feelings, but of milder intensities.  
Kelly et al. 
(2017) (98) 
    
Part A To determine if 
the acute side-
effects resulting 
from β-A 
supplementation 
differed between 
Healthy meat-eating males 
(15) aged 23.5 ± 7.6 
stratified into groups based 
on body mass (< 75 VS 
>85kg) 
1.6g (absolute dose) or 
0.02g.kgBM-1 (relative dose) 
provided as powder dissolved in 
10ml sugar free cordial. The mean 
relative dose corresponded to 
1.33g for the lighter group, and 
Lighter individuals had a reduced incidence and severity of symptoms 
when consuming the absolute dose, while the reverse was true for 
heavier individuals, who experienced a greater incidence and severity 
of symptoms when consuming the relative dose.  
Supplementary Data 
absolute and 
relative doses, and 
whether body 
mass and 
composition were 
related to side 
effects 
experienced.  
1.84g for the heavier.  
Part B To determine if 
paresthesia 
experienced 
following acute 
BA 
supplementation 
is related to high 
intensity exercise 
performance. 
Recreationally trained 
males (12) aged 21.1 ± 4.2 
yrs, who experienced 
paresthesia after ingestion 
of pure BA, but not after 
ingesting sustained 
released BA.  
1.6g provided as either pure or 
sustained release BA.  
Intensities and manifestations of side effects were highest in the pure 
BA condition, followed by the sustained release BA condition, then 
placebo (p < 0.05 for differences between each condition). Side-effects 
experienced were not related to performance outcomes. The occurrence 
of side-effects in individual participants were not consistent between 
trials.  
MacPhee et 
al. (2013) (99) 
To investigate the 
influence of 
ethnicity on the 
acute response to 
beta-alanine 
ingestion.  
Asian (10), and Caucasian 
(10) men and women (ratio 
7/3 in both groups), with 
mean age of 31 yrs.  
3g dose, dissolved in 200ml of an 
artificial fruit flavored drink.  
Both groups experienced paresthesia. Timing, intensity and localisation 
of symptoms were different between the groups, with asians reporting 
a slower onset of paresthesia related symptoms, and of lesser severity 
than caucasians. 
Mor et al. 
(2018) (100) 
To investigate the 
influence of acute 
BA intake on 
blood gas 
responses.  
Male soccer players aged 
19 - 24 yrs (BA n = 9, 
PLA n = 9) 
3g dose, with 250ml of water.  No side-effect information provided.  
Stautemas et 
al. (2018) 
(101) 
To investigate 
blood BA 
pharmacokinetics 
of a single BA 
dose 
supplemented as 
either a fixed, or a 
weight-relative 
dose.  
Male (19) and female (15) 
healthy omnivores, aged 
25.1 ± 4.29 yrs (BA n = 
34, with all 35 consuming 
the weight relative, and 28 
consuming the fixed dose.  
1.4 g (fixed dose, n = 34) or 
10mg.kg.-1day-1.  
None of the participants experienced paresthesia when consuming the 
weight-relative dose. Two reported paresthesia when consuming the 
fixed dose, and the moment of occurrrence matched their individual 
Cmax.  
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Supplemental Table 3: Evidence from animal studies  
Author 
(date) 
Aim Animal BA Dose Primary Outcome 
Abebe et al. 
(2003a) (102) 
To examine the effects of chronic BA 
induced taurine deficiency on the 
reactivity of the rat aorta to adenosine 
receptor simulation.  
10 week old male 
Wistar - Kyoto 
rats. 
3% BA in drinking water for 3 
weeks.  
Endogenous BA induced taurine deficiency caused 
differential inhibitory effects on adenosine receptor 
mediated vasorelaxation, indicating a taurine mediated 
modulation of blood flow regulation.  
Abebe et al. 
(2003b) (103) 
To examine the effects of chronic BA 
induced taurine deficiency on 
vascular reactivity.  
10 week old male 
Wistar - Kyoto 
rats. 
3% BA in drinking water for 3 
weeks.  
BA induced taurine depletion caused enhanced contractile 
responsiveness but depressed relaxation of the rat aorta.  
Allo et al. 
(1997) (104) 
To examine the effect of BA induced 
taurine deficiency on cellular necrosis 
in a regional model of ischemia.  
Male Wistar rats 
weighing 250 - 
300g. 
3% BA in drinking water for 45 
- 28 days.  
BA induced taurine depletion resulted in a cardioprotective 
effect.  
Bhattacharya 
et al. (2015) 
(105) 
To investigate the effects of EGCG, 
BA and wheel running alone or in 
combination on several outcomes 
related to physical fitness, neuronal 
plasticity and cognition.  
117 day old Male 
BALB/cJ mice. 
581.5 ± 4.94 mg.kg.day-1 for 39 
days.  
BA did not influence physical fitness, adult hippocampal 
neurogenesis, or learning and memory measures, whereas 
exercise had robust effect on all of these outcomes. BA 
supplementation resulted in a reduction of body fat 
assessed by MRI.  
Blancquaert 
et al. (2016) 
(106) 
To investigate if BA is degraded by 
the transaminase enzymes GABA-T 
and ACXT2, and if this reaction 
regulates tissue HCD homeostasis.  
Male C57BL/6 
mice, sacrificed at 
80 days. 
0.1, 0.6 or 1.2% BA in drinking 
water for 14 days. Animals in 
the 0.1% group were further 
divided into subgroups based on 
daily s.c. injections with BA 
transaminase inhibitors 
(vigabatrin or AOA). 
Skeletal muscle carnosine content is controlled by 
circulating BA levels, which can be suppressed by hepatic 
and renal BA transamination upon oral BA intake.  
Choi et al. 
(2009) (107) 
To determine if BA supplementation 
influences the hepatoxicity of CCI4. 
Male ICR mice, 
weighing 20 - 
25g. 
3% in drinking water before 
CCI4 treatment.  
BA had a hepatoprotective effect against CCI4, which may 
be acounted for by the increased supply of cysteine for 
production of taurine and/or GSH, both known to have 
important roles in the maintenance of usual hepatic 
physiology.  
Dawson et al. 
(2002) (108) 
To examine the influence of taurine 
supplementation and BA induced 
taurine depletion on indices of 
oxidative damage in a model of 
exercise induced muscle injury.  
Male Sprague-
Dawley rats 
weighing 180 - 
200g 
3% BA in drinking water for 4 
weeks. 
Both BA and taurine supplementation conferred a degree 
of oxidative protection against exercise induced muscle 
injury.  
Ericson et al. 
(2011) (109) 
To investigate the effect of ethanol 
administration on dopamine output in 
Male Wistar rats..  5% BA in drinking water for 5 
weeks.  
BA induced taurine depletion did not prevent ethanol from 
increasing extracellular taurine when perfused in the 
Supplementary Data 
rats with BA induced taurine 
depletion.  
nucleus accumbens.  
Erman et al. 
(2004) (110) 
To investigate the effect of BA 
induced taurine depletion on liver 
fibrosis in an ethandol-CCI4 induced 
cirrhosis model.   
Wistar rats 
weighing 180 - 
220g. 
3% BA in drinking water for 4 
weeks.  
The BA group had normal liver structure, but rare 
monunclear cells in the portal area were present and 
ethanol and CCI4 treated rats proceeded to complete 
cirrhosis.  
Everaert et al. 
(2013) (111) 
To investigate the effect of BA and 
carnosine supplementation on muscle 
contractility 
Naval medical 
research institute 
(NMRI) mice 
weighing 44.6 ± 
6.4g. 
0.6 or 1.2% BA in drinking 
water for 8 - 12 weeks.  
BA supplementation (1.2% only) results in a leftward shift 
in the force-frequency relationship in EDL, and reduced 
fatigability in the soleus during isolated muscle 
contractions.  
Everaert et al. 
(2013)(112) 
To investigate the effect of BA 
supplementation on transcriptional 
events of genes related to HCD 
metabolism.  
Male NMRI mice 
weighing 45.9 ± 
5.9g.  
1.2% BA in drinking water for 8 
weeks.  
CNDP2, TauTm and ABAT mRNA levels were higher and 
CARNS mRNA tended to be higher following 
supplementation. PAT1, PHT2 and HDC expression were 
not affected by BA supplementation.  
Garcia-Ayuso 
et al. (2018) 
(113) 
To examine the influence of BA 
induced taurine depletion on the 
retinal neuron response to light 
exposure.  
Two month old 
albine Sprague 
Dawley female 
rats  (150 - 180g) 
3% BA in drinking water for 
2months.  
BA induced taurine deficiency resulted in retinal 
degradation, which was exacerbated by light exposure.  
Gonzales-
Quevedo et 
al. (2003) 
(114) 
To investigate the effect of BA 
induced taurine depletion on 
biochemical changes induced by 
chronic exposure to low doses of 
methanol.  
Male Sprague-
Dawley rats 
weighing 154 ± 
23g. 
5% BA in drinking water for 2 
weeks, followed by 3% for a 
further 4 weeks.  
BA supplementation decreased taurine i in the plasma, 
hippocampus and posterior cortex, but not in the retina and 
optic nerve, with subsequent impact on glycinergic activity 
and aspartate metabolism.  
Harada et al. 
(1990) (115) 
To investigate the effects of BA 
induced taurine deficiency on cardiac 
calcium metabolism and redox 
mechanisms following doxorubicin 
administration.  
Male Wistar rats..  3% BA in drinking water for 3 - 
4 weeks.  
Taurine deficiency per se did not impact cardiac calcium 
levels, but increased doxorubicin induced calcium 
accumulation, which may have resulted from an inhibition 
of ATP-dependent CA2+ uptake in isolated cardiac 
sarcolemmal vesicles. Taurine deficiency did not increase 
MDA content, but enhanced the doxorubicin mediated 
increase in myocardial MDA levels.  
Hoffman et 
al. (2015) 
(116) 
To investigate the effect of BA 
supplementation on PTSD like 
behavioural changes in rodents 
exposed to a predator scent stress.  
Male Sprague-
Dawley rats 
weighing 200 - 
250g.  
80 mg.kgBM-1 for 30 days.  BA supplementation attenuated some, but not all of the 
behaviours associated with PSS, which may have been 
related to an increase in brain carnosine and a subsequent 
protection of hippocampal BDNF expression.  
Hoffman et 
al. (2017) 
(117) 
To investigate the effect of BA 
supplementation on behavioural, 
cognitive and biochemical responses 
Male Sprague-
Dawley rats 
weighing 200 - 
80 mg.kgBM-1 for 30 days.  The BA treated rats has a reduced incidence of mTBI, 
along with a reduced inflammatory response and higher 
hippocampal BDNF expression following blast exposure.  
Supplementary Data 
to mTBI and PTSH in rats exposed to 
a low-intensity blast wave.  
250g.  
Horvath et al. 
(2016) (118) 
To investigate the effect of BA 
induced taurine deficiency on muscle 
contractility and fatigue in wild-type 
and mdx mice.  
C57BL/10 wild 
type and mdx 
mice aged 4.5 
months.  
3% BA in drinking water for 4 
weeks.  
BA supplementation enhanced fatigue resistance in both 
the WT and the mdx fast-twitch muscle.  
Ideishi et al. 
(1994) (119) 
To determine if BA induced taurine 
deficiency reduces blood pressure by 
stimulating the renal kallikrein-kinin 
system.  
Male Dahl S rats 
aged 4 - 16 
weeks. 
2% BA in drinking water, along 
with a high-salt (8%) diet for 4 
weeks. 
Taurine appears to be an effective antihypertensive agent 
for salt-induced hypertension, which may involve the 
activation of renal kallikrein.  
Jin et al. 
(2005) (120) 
To investigate the effect of BA 
induced taurine deficiency on seizure 
activity, neuronal cell death and 
transporter expression during kainic 
acid induced epilepsy.  
Male sprague-
dawley rats 
weighing 140 - 
160g. 
3% BA in drinking water for 10 
days.  
BA induced taurine deficient rats were more susceptible to 
KA-induced epilepsy.  
Kaczmarek et 
al. (2016) 
(121) 
To investigate the effect of BA 
supplementation on contractile 
function in fast and slow motor units.  
Adult male Wistar 
rats aged 6 
months.  
1% BA in drinking water for 10 
weeks.  
BA supplementation induced a number of contractile 
adaptations, along with enhanced fatigue resistance.  
Kerai et al. 
(2001) (122) 
To investigate the effect of BA 
induced taurine depletion on the 
pathological and biochemical lesions 
induced by alcohol.  
Female sprague 
dawley rats 
weighing 125 - 
150g  
3% BA in drinking waer for 2 
days (BA group n = 12), 
followed by the co-
administration of alchohol and 
BA for a further 28 days.  
BA supplementation increased the hepatoxicity of ethanol.  
Kim et al. 
(2002) (123) 
To investigate the effect of BA 
induced taurine depletion on 
lipolysaccharide inducted 
hepatoxicity.  
Male Sprague-
Dawley rats 
weighting 230 - 
280 g. 
3% BA in drinking water for 7 
days prior to LPS challenge.  
BA induced hepatic taurine depletion did not affect the 
hepatoxic outcome measures in this study. AST decreased 
in response to BA treatment.  
Lake et al. 
(1988) (124) 
To investigate if oral or injected BA 
depletes heart or retinal taurine.   
Male sprague 
dawley rats 
weighing 250 - 
270 g.  
3% BA in drinking water, with 
animals analysed after 1, 2 and 
3 weeks of treatment.  
Oral BA treatment showed weight gain in comparison to 
controls. Oral BA treatment led to a significant reduction 
of heart taurine after 1, 2 and 3 weeks. The magnitude of 
treatment was less after 3 weeks, and by 6 weeks the BA 
group were not different to controls. Retinal taurine content 
was not different.  
Lee et al. 
(2007) (125) 
To investigate the effect of BA 
induced taurine deficiency on CCI4 
induced acute hepatotoxicity.  
Male ICR mice 
weighing 20 - 
25g.  
3% in drinking water for 1 
week.  
BA protected against CCI4 induced hepatotoxicity, 
potentially through increased cysteine availability.  
Lilequist et 
al. (1982) 
To examine the influence of BA and 
LA on the exploratory activity of 
Spontaneously 
hypertensive 
1% in drinking water for 7 days.  BA treatment inhibited the exploratory activity of the 
spontaneously hypertensive, but not the normostensive rats.  
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(126) spontaneoulsy hypertensive and 
normotensive rats. 
(SHR) or 
normotensive 
Wistar Kyoto rats 
(WKR)aged 3 
months. 
Liu et al. 
(2012) (127) 
To investigate the molecular and 
neural mechanisms of itch and 
tingling induced by BA ingestion.  
MgrgprD 
knockout or WT 
mice aged 2 - 3 
months.  
40mg.ml-1 of BA in a vehicle of 
5% sucrose in water.  
Comparison of response in MrgpgD knockout versus WT 
mice showed that BA directly induces itch in an MrgrprD 
dependent manner.  
Lu et al. 
(1996) (128) 
To investigate the effect of BA 
supplementation on the brain in 
taurine depleted and replete cats.  
Female domestic 
cats who were fed 
on a taurine free, 
or 0.05% taurine 
diet for at least 2 
years prior to the 
study.  
5 cats in each group (taurine 
depleted or replete) were fed 5% 
BA in drinking water for 20 
weeks.  
BA supplementation caused a similar reduction of taurine 
in both groups of cats, but more BA accumulated in the 
brains of the taurine deprived compared to the taurine 
replete cats. The cerebellum of cats treated with BA had a 
number of pathological changes compared to non-BA 
treated cats. These neurotoxic changes appeared to be 
related to BA accumulation rather than taurine deficiency.  
McBroom et 
al. (1996) 
(129) 
To investigate mechanisms through 
which taurine may disrupt the ability 
to deal with a saline load.  
Male and female 
adult Wistar rats 
(> 150g)  
0.1 or 0.2M BA, with and 
without the co-ingestion of 
saline and taurine. 
Taurine intake induced hypernatremia and appeared to 
interfere with normal homeostatic control mechanism, so 
exacerbating  the hypernatremic response to saline 
ingestion and 3 of the 12 rats in this group died. BA 
ingestion counteracted this effect.  
Mei et al. 
(1998) (130) 
To determine if dietary histidine and 
BA supplementation increase HCD 
content and oxidative stability of 
pork muscle.  
Hampshire-
Yorkshire 
crossbred pigs, 
initially averaging 
65kg body 
weight.  
0.225% BA or o.225 + 0.4% 
histidine.  
BA supplementation did not consistently increase or 
dramatically increase the oxidative stability of muscle 
which had been cooked or salted.  
Miyaji et al. 
(2012) (131) 
To investigate the tissue distribution 
of ATPGD1 mRNA and ATPGD1 
and CN1 expression profiles in 
reponse to carnosine or BA 
administration.  
Male SPF-bred 
ddY mice, 
weighing 34 g. 
Mice were orally provided 
2g.kg-1 of BA, then sacrificed 
after 15, 30, 60, 120, 180 or 360 
mins of treatment.  
ATPGD1 mRNA level increased at 1 and 3 hours post BA 
administration.  
Mozaffari et 
al. (1986) 
(132) 
To investigate the effect of BA 
induced taurine deficiency on 
myocardial contracility and 
carbohydrate metabolism.  
Male Wistar rats, 
weighing 240 - 
260g.  
3% BA in drinking water for 3 
weeks.  
BA treatment did not impact myocardial contraction, but 
did stimulate an increased glycolytic rate and lactate 
production.   
Mozaffari et 
al. (1997) 
To investigate if BA induced taurine 
depletion affects renal excretory 
6-week old male 
WKY rats. 
3% BA in drinking water for 3 
weeks.  
Renal extraction of fluid and sodium after exposure to the 
saline load was lower in the BA treated group. Short term 
Supplementary Data 
(133) responses induced by the 
administration of a saline load.  
BA treatment (2 days) increased sodium excretion without 
altering fluid excretion.  
Mozaffari et 
al. (1998) 
(134) 
To investigate the effect of BA 
induced taurine deficiency on renal 
excretory responses to hypotonic and 
hypertonic saline infusion.  
7 week old male 
Wistar Kyoto rats. 
3% BA in drinking water for 3 
weeks.  
BA induced taurine depletion altered the natriuretic and 
diuretic responses of the kidney to a hypotonic, but not 
hypertonic saline solution.  
Mozaffari et 
al. (2000) 
(135) 
To investigate the effect of BA 
induced taurine depletion on the 
cardiovascular response to vasoactive 
agents.  
7 week old male 
Wistar-Kyoto 
rats. 
3% BA in drinking water for 3 
weeks.  
BA induced taurine depletion does not impair baroreflex 
function, but does reduce pressor, but not heart-rate 
response to systemic administration of angiotensin II.  
Mozaffari et 
al. (2006) 
(136) 
To invesigate if BA induced taurine 
deficiency impacts renal and blood 
pressure responses to the loss of one 
kidney and/or dietary NaCL excess.  
Male Wistar-
Kyoto rats aged 7 
- 8 weeks. 
3% in drinking water for 2 
weeks.  
BA induced taurine deficiency modulates renal adaptation 
to combined uninephrectomy and dietart NaCL excess, 
resuling in an accelerated development of hypertension.  
Murakami et 
al. (2010) 
(137) 
To investigate if a taurine or beta-
alanine supplementation impacts 
stress response.  
Male ICR mice 
aged 3 weeks.  
22.5mmol/kg-1 BA in a powder 
diet for approximately 4 weeks.  
BA treatment resulted in anxiolytic-like effects as 
evidenced by improved performance in the elevated plus-
maze test. This may have been mediated through altered 
hypothalamic 5-HIAA and hippocampal BDNF 
concentrations.  
Naderi et al. 
(2016) (138) 
To investigate the influence of BA 
supplementation on muscle carnosine 
and exercise induced lactate 
production.  
Male wistar rats 
aged 2 months. 
1.8% BA in drinking water for 4 
weeks.  
BA supplementation increased muscle carnosine and 
reduced serum lactate.  
Naderi et al. 
(2017) (139) 
To determine if glucose feeding 
during BA supplementation would 
enhance muscle carnosine 
concentration.  
Male Wistar rats..  1.8% BA or 1.8% BA + 5% 
glucose in drinking water for 4 
weeks.  
Both BA groups increased muscle carnosine content, but 
the co-ingestion of BA and glucose did not have any 
additive effects.  
Pansani et al. 
(2012) (140) 
To investigate the influence of BA 
induced taurine deficiency on cardiac 
structure, function and metabolism.  
Male wistar rats 
weighing 100g  
3% BA in drinking water for 30 
days.  
BA induced taurine deficiency resulted in cardiac atrophy, 
as indicated by thinning of the ventricular wall, reduced 
left ventricular dry weight, decreated myocyte cross-
sectional area and increased oxidative stress.  
Parildar et al. 
(2007) (141) 
To investigate the effect of BA 
induced taurine depletion on 
endogenous and induced lipid 
peroxidation levels in liver, brain, 
heart and erythrocytes and on hepatic 
pro and anti-oxidant balance.  
Male Wistar rats 
weighing 180 - 
200g 
3% BA in drinking water for 1 
month.  
BA induced taurine depletion did not impact any of the 
assessed oxidative or anti-oxidative indicators.  
Parildar et al. To investigate the effect of BA Young (5mo) and 3% BA in drinking water for 6 AA and NADPH induced peroxidation was increased in the 
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(2008) (142) induced taurine depletion on lipid 
peroxidation potential and the 
antioxidant system of aged rats.  
old (22mo) male 
Wistar rats  
weeks.  hearts of aged rats following BA treatment.  
Qi et al. 
(2018) (143) 
To examine the effect of BA 
supplementation on growth 
performance, meat quality, 
antioxidant ability, carnosine content 
and carnosine related gene activity in 
broiler chicks.  
1 day old Arbor 
Acres broilers.  
250, 500, 1000 or 2000 mg/kg 
feed for 42 days.  
Dietary BA intake improved growth performance, 
carnosine content, ameliorated antioxidant capacity and 
meat quality and upregulated the gene expression of 
carnosine synthesis related enzymes.  
Saad et al. 
(2002) (144) 
To investigate the effect of BA 
induced taurine depletion on the 
degree of CDDP-induced 
nephrotoxicity.  
Male Wistar rats 
weighing 150 - 
200g  
3% BA in drinking water for 1 
week.  
BA induced taurine depletion resulted in increased serum 
creatinine, BUN and kidney mDA production in 
comparision with controls.  
Seabra et al. 
(1997) (145) 
To investigate the effect of BA 
induced taurine depletion on 
methylene dianiline induced 
hepatotoxicity.  
Male sprague-
dawley rats 
weighing 130 - 
270g  
3% in drinking water for 7 days.  BA induced taurine depletion increased DAPM toxicity.  
Stegen et al. 
(2015) (146) 
To investigate whether the metabolic 
protection afforded by carnosine 
occurs at the tissue or plasma level.  
3 week old male 
sprague-dawley 
rats  
1% BA in drinking water for 8 
weeks.  
Plasma, but not muscle carnosine is is involved in 
preventing early-stage lipoxidation in the 
circulation and inflammatory signaling in the muscle of 
rats. 
Sturman et 
al. (1996) 
(147)  
To investigate the effect of BA intake 
on taurine levels in cats.  
Female domestic 
cats   
5% BA in drinking water  BA intake reduced the taurine content of both taurine 
supplemented and taurine deprived cats. BA appeared to 
induce a neurotoxic effect in cats.  
Vallejo et al. 
(2016) (148) 
To investigate the independent and 
combined influence of HMB and BA 
supplementation on muscle 
contractility in a pre-clinical model of 
sarcopenia.  
Male 
C57BL/6NTac 
mice sacrificed at 
19 months old.  
Purified diet containing 411 
mg.kg-1BW BA for 8 weeks 
(BA group n = 12) 
BA treatment increased absolute EDL twitch force, 
maximal tetanic force and the rate of force development.  
Waterfield et 
al. (1993) 
(149) 
To investigate the effect of BA 
induced hepatic taurine depletion on 
CCI4 induced hepatotoxicity.  
Male Sprague-
Dawlet rats, 
weighing 270 - 
320 g.  
3% BA in drinking water for 6 
days. 
BA treatment increased the hepatotoxicity of single CCI4 
doses.  
Yang et al. 
(2010) (150) 
To investigate the effects of taurine 
supplementation and BA induced 
taurine depletion on reproductive 
indicators.  
Wistar rats of 
different ages.  
1% BA in drinking water for 22 
days. 
BA treatment reduced reproductive hormone level and 
reduced semen quality in aged rats.   
Zhang et al. To investigate the effect of BA Rats 3% BA in drinking water for 5 BA treated rats had increased chemiluminescence 
Supplementary Data 
(1998) (151) induced taurine depletion on lung 
macrophages.  
weeks.  production in the macrophages isolated from the lungs, but 
no change to superoxide dismutase activity.  
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